[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 100
1. Bramwell V: When to consider adjuvant/neoadjuvant therapy for adult soft-tissue sarcoma. Oncology (Williston Park); 2007 Apr;21(4):511-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] When to consider adjuvant/neoadjuvant therapy for adult soft-tissue sarcoma.
  • In patients with adult soft-tissue sarcoma (ASTS), the use and timing of adjuvant chemotherapy or chemoradiotherapy remains controversial.
  • The appropriate target population is generally accepted as International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) stage III extremity or trunk sarcomas (i.e., >5 cm, grade 3/4, located deep to the superficial fascia, with no evidence of metastases).
  • [MeSH-major] Neoadjuvant Therapy. Neoplasm Recurrence, Local. Sarcoma / drug therapy. Sarcoma / radiotherapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Humans. Meta-Analysis as Topic. Randomized Controlled Trials as Topic. Retrospective Studies

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474349.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Congresses
  • [Publication-country] United States
  •  go-up   go-down


2. Lucas DR, Kshirsagar MP, Biermann JS, Hamre MR, Thomas DG, Schuetze SM, Baker LH: Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation. Oncologist; 2008 Apr;13(4):451-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation.
  • Histologic response to chemotherapy is generally regarded as an independent prognostic variable in bone sarcomas, both osteosarcoma and Ewing's sarcoma.
  • In soft tissue sarcomas, however, descriptions of histologic alterations from chemotherapy and correlative outcome studies are much more limited.
  • Herein we report clinicopathological findings from a homogeneously treated group of 31 patients with tumor stage T2 grade 3 extremity soft tissue sarcomas treated with the same neoadjuvant chemotherapy followed by surgical excision, treated by the same medical oncologist and orthopedic surgeon.
  • Chemotherapy induces profound tissue alterations in soft tissue sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoadjuvant Therapy. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Male. Middle Aged. Prognosis. Prospective Studies. Treatment Outcome


3. Latt LD, Turcotte RE, Isler MH, Wong C: Case series. Soft-tissue sarcoma of the foot. Can J Surg; 2010 Dec;53(6):424-31
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case series. Soft-tissue sarcoma of the foot.
  • BACKGROUND: We reviewed cases of soft-tissue sarcoma of the foot to gain insight into the presentation, treatments and outcomes for this rare disease and to determine whether limb-salvage surgery yields reasonable functional and oncological outcomes.
  • METHODS: We reviewed the cases of 16 patients treated by 2 of us (R.T. and M.I.) for soft-tissue sarcoma of the foot over a 15-year period.
  • We extracted the following information from each patient's medical record: disease status at presentation, prior treatment, histological diagnosis, American Joint Committee on Cancer (AJCC) stage, details of treatment, oncological outcome and functional outcome.
  • Histological diagnosis was synovial sarcoma for 7 of 16 patients.The tumours were evenly distributed among the hindfoot, midfoot and forefoot.
  • Most patients (n = 13) presented with AJCC stage II or III disease.
  • Free tissue transfer (n = 9) and radiation therapy (n = 12) were used in most cases.
  • Second, limb salvage was usually possible, but it required accepting marginal resections, relying on free tissue transfer to obtain coverage and using radiation therapy to obtain local control.
  • [MeSH-major] Foot / surgery. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Amputation / statistics & numerical data. Female. Follow-Up Studies. Free Tissue Flaps / statistics & numerical data. Humans. Limb Salvage / statistics & numerical data. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Radiotherapy, Adjuvant / statistics & numerical data

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Foot Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Apr;36(6):710-6 [10762742.001]
  • [Cites] Foot Ankle Int. 2008 Jul;29(7):690-8 [18785419.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):679-85 [11078615.001]
  • [Cites] Acta Orthop Scand. 2000 Oct;71(5):488-95 [11186407.001]
  • [Cites] J Bone Joint Surg Br. 2001 Nov;83(8):1149-55 [11764430.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):424-34 [11882765.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] J Orthop Surg (Hong Kong). 2002 Dec;10(2):173-8 [12493931.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):485-92 [12518373.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):476-82 [15078635.001]
  • [Cites] J Clin Oncol. 1985 Oct;3(10):1344-8 [4045526.001]
  • [Cites] Semin Oncol. 1989 Aug;16(4):289-96 [2667143.001]
  • [Cites] J Bone Joint Surg Br. 1993 Jul;75(4):658-60 [8331127.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1652-9 [8156492.001]
  • [Cites] Acta Orthop Scand Suppl. 1994 Jun;259:1-31 [8042499.001]
  • [Cites] Acta Orthop Scand. 1994 Oct;65(5):553-8 [7801762.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] Qual Life Res. 1996 Oct;5(5):508-16 [8973131.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):646-52 [9053489.001]
  • [Cites] J Pediatr Surg. 1997 Aug;32(8):1181-4 [9269966.001]
  • [Cites] J Surg Oncol. 1997 Oct;66(2):81-7 [9354161.001]
  • [Cites] Arch Phys Med Rehabil. 1999 Jun;80(6):615-8 [10378484.001]
  • [Cites] Ann Surg Oncol. 2005 Jan;12(1):10-7 [15827772.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Am J Clin Oncol. 2006 Feb;29(1):62-5 [16462505.001]
  • [Cites] J Surg Oncol. 2000 Apr;73(4):206-11 [10797333.001]
  • (PMID = 21092437.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2993038
  •  go-up   go-down


Advertisement
4. Liebl LS, Elson F, Quaas A, Gawad KA, Izbicki JR: Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma. Anticancer Res; 2007 Jul-Aug;27(4C):2897-902
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma.
  • BACKGROUND: Pulmonary metastasectomy in soft tissue sarcoma (STS) can lead to long-term survival.
  • Subgroup analysis was performed on age, primary tumor stage, histological type and grade, occurrence and recurrence pattern, systemic treatment and number of resections.
  • [MeSH-major] Lung Neoplasms / secondary. Lung Neoplasms / surgery. Sarcoma / secondary. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Humans. Middle Aged. Neoplasm Staging. Reoperation. Survival Rate. Treatment Outcome


5. Zhang B, Tomita Y, Ch'ng E, Qiu Y, He J, Jin YF, Tomoeda M, Hamada K, Ueda T, Aozasa K: Prognostic significance of phosphorylated FOXO1 expression in soft tissue sarcoma. Ann Surg Oncol; 2009 Jul;16(7):1925-37
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of phosphorylated FOXO1 expression in soft tissue sarcoma.
  • Expression of FOXO1 in soft tissue sarcoma (STS) and its correlation with clinicopathological factors and prognostic significance were evaluated.
  • METHODS: Expression of phosphorylated FOXO1 (p-FOXO1) in localized STS from 84 adult patients, 50 male and 34 female, aged 15-89 (median 54) years, was evaluated by immunohistochemistry.
  • Nuclear p-FOXO1 expression correlated with mitotic count, and cytoplasmic p-FOXO1 expression with histological subtype, mitotic count, cellularity, myxoid change, Ki-67 labeling index, histological grade, American Joint Committee on Cancer stage, and patient age.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Forkhead Transcription Factors / biosynthesis. Sarcoma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Phosphorylation. Prognosis. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408047.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


6. Talbot SG, Mehrara BJ, Disa JJ, Wong AK, Pusic A, Cordeiro PG, Athanasian EA: Soft-tissue coverage of the hand following sarcoma resection. Plast Reconstr Surg; 2008 Feb;121(2):534-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue coverage of the hand following sarcoma resection.
  • The importance of obtaining widely negative margins has increased the complexity of operations and the importance of soft-tissue and bony reconstruction.
  • The authors review the experience at a single institution of hand reconstruction following sarcoma resection based on prospectively collected data.
  • METHODS: Data were collected for all patients undergoing sarcoma resection by a single surgeon.
  • Variables evaluated included patient demographics, tumor pathologic findings, location, size, depth, grade, stage, method of resection and reconstruction, adjuvant therapies, complications, and patient outcomes.
  • The most common abnormalities were epithelioid sarcoma (n = 9), soft-tissue malignant fibrous histiocytoma (n = 8), synovial sarcoma (n = 6), and fibrosarcoma (n = 4).
  • CONCLUSIONS: The choice of hand reconstruction method following sarcoma resection depends on a complete knowledge of options, risks, and benefits.
  • Extensive use of a limited number of techniques by the authors' institution appears to contribute to excellent success and complication rates, with safe, reliable, and effective soft-tissue coverage.
  • [MeSH-major] Hand. Reconstructive Surgical Procedures / methods. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation / methods. Biopsy. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Retrospective Studies. Surgical Flaps. Survival Rate. Treatment Outcome. United States / epidemiology


7. Papanastassiou I, Ioannou M, Magoulas D, Lalos S, Athanassiou AE, Ziras N, Thanopoulou E, Demertzis N: Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma. J BUON; 2009 Jul-Sep;14(3):507-10
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoembolization facilitates limb salvage surgery in stage III soft tissue sarcoma.
  • A 26 year-old male was referred to our unit because of a stage III soft tissue sarcoma in the shoulder girdle-axillary area and reduced forearm-distal arm strength.
  • In stage III soft tissue sarcomas, especially in proximity with major nerve/arterial bundles, a multimodality approach is mandatory; chemoembolization is very effective in shrinking the tumor and defining its margins so as to make feasible a LSS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Embolization, Therapeutic. Limb Salvage. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Phytogenic / therapeutic use. Chemotherapy, Adjuvant. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Neoplasm Staging. Radiotherapy, Adjuvant. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19810146.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


8. Almeida PS, Manoel WJ, Reis AA, Silva ER, Martins E, Paiva MV, Fraga AC Jr, Saddi VA: TP53 codon 72 polymorphism in adult soft tissue sarcomas. Genet Mol Res; 2008;7(4):1344-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 codon 72 polymorphism in adult soft tissue sarcomas.
  • Soft tissue sarcomas (STS) are tumors of mesodermal origin, comprising about 1% of all adult neoplasms.
  • In the STS group, p53 codon 72 polymorphic variants were not significantly associated with gender, age, tumor size, clinical stage, tumor grade, histology, or nodal or distant metastasis.
  • The five-year overall survival rate for the STS group was 48%; it was significantly affected by tumor grade, clinical stage, and nodal and distant metastasis.
  • Soft tissue sarcoma patients with the Pro/Pro variant had a reduced survival rate (30%), when compared to the p53 Arg/Arg (45%) and the p53 Arg/Pro groups (55%).
  • [MeSH-major] Codon / genetics. Polymorphism, Genetic. Sarcoma / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arginine / genetics. Female. Gene Frequency. Genes, p53. Genetic Predisposition to Disease. Genotype. Humans. Male. Middle Aged. Proline / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065769.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Codon; 0 / Tumor Suppressor Protein p53; 94ZLA3W45F / Arginine; 9DLQ4CIU6V / Proline
  •  go-up   go-down


9. Davidge K, Bell R, Ferguson P, Turcotte R, Wunder J, Davis AM: Patient expectations for surgical outcome in extremity soft tissue sarcoma. J Surg Oncol; 2009 Oct 1;100(5):375-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient expectations for surgical outcome in extremity soft tissue sarcoma.
  • This study examines the relationship between pre-treatment outcome expectations and post-operative function and health-related quality of life (HRQoL) in patients with extremity soft tissue sarcoma (ESTS).
  • Education, dispositional optimism, tumor location, AJCC stage, and baseline function/HRQoL were significant predictors of patient expectations.
  • [MeSH-major] Attitude to Health. Limb Salvage. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Educational Status. Extremities / surgery. Female. Humans. Male. Middle Aged. Multivariate Analysis. Quality of Life. Recovery of Function. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19444815.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Moncrieff MD, Kroon HM, Kam PC, Stalley PD, Scolyer RA, Thompson JF: Isolated limb infusion for advanced soft tissue sarcoma of the extremity. Ann Surg Oncol; 2008 Oct;15(10):2749-56
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb infusion for advanced soft tissue sarcoma of the extremity.
  • We report our experience with ILI for the treatment of soft tissue sarcoma (STS).
  • Only American Joint Committee on Cancer stage was associated with overall survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Extremities / pathology. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Dactinomycin / administration & dosage. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648882.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; Q41OR9510P / Melphalan
  •  go-up   go-down


11. Lahat G, Tuvin D, Wei C, Anaya DA, Bekele BN, Lazar AJ, Pisters PW, Lev D, Pollock RE: New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol; 2008 Oct;15(10):2739-48
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New perspectives for staging and prognosis in soft tissue sarcoma.
  • BACKGROUND: Data suggest that the current American Joint Committee on Cancer (AJCC) soft tissue sarcoma (STS) staging criteria merit further evaluation.
  • METHODS: Prospectively accrued data were analyzed for 1,091 AJCC stage I to III primary STS patients who had complete macroscopic resection at our institution from 1996 to 2007.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Oct;15(10):2643 [18685895.001]
  • (PMID = 18521685.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Jakob J, Wenz F, Dinter DJ, Ströbel P, Hohenberger P: Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. Int J Radiat Oncol Biol Phys; 2009 Nov 1;75(3):810-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma.
  • PURPOSE: To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS).
  • PATIENTS AND METHODS: A cohort of 15 consecutive patients with nonmetastasized, primary high-grade or locally recurrent Stage III (n = 14) or IIb (n = 1) STS not amenable to surgical resection without significant organ or extremity function loss was prospectively investigated.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Dacarbazine / analogs & derivatives. Radiotherapy, Intensity-Modulated. Sarcoma
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Female. Humans. Male. Middle Aged. Nausea / etiology. Postoperative Complications. Prospective Studies. Radiation Injuries / etiology. Radiotherapy Dosage. Remission Induction. Tumor Burden. Vomiting / etiology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307066.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


13. Al-Refaie WB, Habermann EB, Jensen EH, Tuttle TM, Pisters PW, Virnig BA: Surgery alone is adequate treatment for early stage soft tissue sarcoma of the extremity. Br J Surg; 2010 May;97(5):707-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery alone is adequate treatment for early stage soft tissue sarcoma of the extremity.
  • BACKGROUND: Evolving evidence suggests that, in selected patients with tumour category 1 (T1) extremity soft tissue sarcoma (ESTS), surgery alone offers satisfactory results without decreasing survival.
  • This study assessed the effect of sarcoma treatments on survival outcomes of T1 ESTS in a population-based data set.
  • Multivariable analysis was used to assess the impact of radiotherapy on overall survival (OS) and sarcoma-specific survival (SSS), adjusting for co-variables.
  • [MeSH-major] Extremities. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 British Journal of Surgery Society Ltd.
  • (PMID = 20235085.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Oda Y, Tateishi N, Matono H, Matsuura S, Yamamaoto H, Tamiya S, Yokoyama R, Matsuda S, Iwamoto Y, Tsuneyoshi M: Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. Int J Cancer; 2009 Apr 15;124(8):1852-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma.
  • We measured CXCR4 expression levels in soft-tissue sarcoma and compared them with VEGF expression or microvessel density (MVD).
  • Within the different types of tumor tissue, the expression levels of CXCR4 (p < 0.0001) and VEGF (p < 0.0001) in MNRCTs were significantly higher than those in intermediate tumors or MRCTs.
  • Moreover, both univariate (p < 0.0001) and Cox multivariate analysis (p = 0.0001) revealed that overexpression of CXCR4 was an independent adverse prognostic factor, in addition to high stage according to the American Joint Committee on Cancer and a high MIB-1-LI.
  • Determination of the CXCR4 expression level as a novel marker can provide useful prognostic information for patients and it could be a candidate for molecular targeting therapy in MNRCTs of soft-tissue sarcomas.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Receptors, CXCR4 / biosynthesis. Sarcoma / metabolism. Sarcoma / mortality. Soft Tissue Neoplasms / metabolism. Soft Tissue Neoplasms / mortality. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Biomarkers, Tumor / metabolism. Cell Survival. Female. Humans. Immunohistochemistry / methods. Male. Microcirculation. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19107931.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCR4 protein, human; 0 / Receptors, CXCR4; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


15. Dantonello TM, Int-Veen C, Harms D, Leuschner I, Schmidt BF, Herbst M, Juergens H, Scheel-Walter HG, Bielack SS, Klingebiel T, Dickerhoff R, Kirsch S, Brecht I, Schmelzle R, Greulich M, Gadner H, Greiner J, Marky I, Treuner J, Koscielniak E: Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol; 2009 Mar 20;27(9):1446-55
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults.
  • PURPOSE: To improve risk-adapted therapy for localized childhood soft tissue sarcoma within an international multicenter setting.
  • PATIENTS AND METHODS: Four hundred forty-one patients younger than 21 years with localized rhabdomyosarcoma and rhabdomyosarcoma-like tumors (ie, extraosseous tumors of the Ewing family, synovial sarcoma, and undifferentiated sarcoma) were eligible.
  • Therapy was stratified according to postsurgical stage, histology, and tumor site.
  • EFS/OS rates by histology were 60% +/- 5%/72% +/- 5% in rhabdomyosarcoma, 62% +/- 10%/69% +/- 10% for Ewing tumors of soft tissues, 84% +/- 12%/90% +/- 10% for synovial sarcoma, and 67% +/- 38%/83% +/- 30% for undifferentiated sarcoma, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Dactinomycin / administration & dosage. Dose Fractionation. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Infant. Infant, Newborn. Male. Rhabdomyosarcoma / therapy. Sarcoma, Ewing / therapy. Sarcoma, Synovial / therapy. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224858.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


16. Hoffmann AC, Danenberg KD, Taubert H, Danenberg PV, Wuerl P: A three-gene signature for outcome in soft tissue sarcoma. Clin Cancer Res; 2009 Aug 15;15(16):5191-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A three-gene signature for outcome in soft tissue sarcoma.
  • PURPOSE: Finding markers or gene sets that would further classify patients into different risk categories and thus allow more individually adapted multimodality treatment regimens in soft tissue sarcomas is necessary.
  • EXPERIMENTAL DESIGN: Formalin-fixed paraffin-embedded tissue samples were obtained from 45 patients with soft tissue sarcoma (median age 57 years, range 16-85 years).
  • A combined factor of these three genes showed a relative risk for shorter survival of 5.5, more than twice higher as in an increasing International Union against Cancer Stage.
  • CONCLUSIONS: Measuring HIF1a, HB-EGF, and VEGF-C expression may contribute to a better understanding of the prognosis of patients with soft tissue sarcoma and may even play a crucial role for the distribution of patients to multimodal therapeutic regimens.
  • [MeSH-major] Gene Expression Profiling. Hypoxia-Inducible Factor 1, alpha Subunit / genetics. Intercellular Signaling Peptides and Proteins / genetics. Sarcoma / genetics. Vascular Endothelial Growth Factor C / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Neoplastic. Heparin-binding EGF-like Growth Factor. Humans. Male. Middle Aged. Models, Biological. Prognosis. Sensitivity and Specificity. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Clin Cancer Res. 2009 Oct;15(20):6472. Hoffman, Andreas-Claudius [corrected to Hoffmann, Andreas-Claudius]
  • (PMID = 19671876.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HBEGF protein, human; 0 / HIF1A protein, human; 0 / Heparin-binding EGF-like Growth Factor; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Intercellular Signaling Peptides and Proteins; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


17. Takeuchi A, Tsuchiya H, Yamamoto N, Hayashi K, Yamauchi K, Kawahara M, Miyamoto K, Tomita K: Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome. Anticancer Res; 2007 Sep-Oct;27(5B):3489-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: long-term clinical outcome.
  • The present study was performed to assess the efficacy of caffeine-potentiated chemotherapy for high-grade soft tissue sarcoma (STS).
  • PATIENTS AND METHODS: A non-randomised prospective clinical trial was initiated for 90 patients with non-metastatic (stages II and III) or metastatic (stage IV) STS.
  • The local recurrence rate was 23.7% in stages II and III and 13.6% in stage IV.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Caffeine / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Disease-Free Survival. Drug Synergism. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Preoperative Care. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972506.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3G6A5W338E / Caffeine
  •  go-up   go-down


18. Zong XY, Yu Y, Yang HJ: Oxaliplatin-dacarbazine combination chemotherapy for the treatment of advanced soft tissue sarcoma of the limbs. J Exp Clin Cancer Res; 2009;28:119
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin-dacarbazine combination chemotherapy for the treatment of advanced soft tissue sarcoma of the limbs.
  • BACKGROUND: This study was designed to explore the feasibility, safety, and outcomes of pre-operative oxaliplatin-dacarbazine combination therapy for the treatment of advanced soft tissue sarcoma (STS) of the limb.
  • PATIENTS AND METHODS: Between November 2005 and November 2008, 31 patients with advanced limb STS classified with stage IV STS were randomly assigned into experimental or control groups, and both were given 2 cycles of chemotherapy before undergoing surgery.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Dacarbazine / administration & dosage. Organoplatinum Compounds / administration & dosage. Sarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Extremities. Female. Humans. Middle Aged. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2004 Jul;15(7):1123-9 [15205208.001]
  • [Cites] Surgeon. 2005 Jun;3(3):216-23 [16076008.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8422-30 [16293873.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):619-25 [16446334.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1776-84 [16541435.001]
  • [Cites] Am J Clin Dermatol. 2008;9(4):207-17 [18572972.001]
  • [Cites] BMC Cancer. 2006;6:160 [16780601.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3844-51 [16921036.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Nov;60(2):112-30 [16949832.001]
  • [Cites] Eur J Surg Oncol. 2006 Dec;32(10):1242-8 [16793237.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Dec;26(4):571-4 [18365554.001]
  • [Cites] Ann Surg Oncol. 2006 Jun;13(6):864-71 [16614886.001]
  • (PMID = 19709417.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 5J49Q6B70F / Vincristine; 7GR28W0FJI / Dacarbazine; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC2739518
  •  go-up   go-down


19. Torigoe T, Terakado A, Suehara Y, Kurosawa H, Yazawa Y, Takagi T: Bone versus soft-tissue sarcomas in the elderly. J Orthop Surg (Hong Kong); 2010 Apr;18(1):58-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone versus soft-tissue sarcomas in the elderly.
  • PURPOSE: To compare survival rates in the elderly with bone versus soft-tissue sarcomas.
  • METHODS: Records of 12 men and 8 women aged 70 to 91 (mean, 77) years with bone or soft-tissue sarcomas were retrospectively reviewed.
  • The grade, size, location, and stage of the sarcomas, as well as their surgical margins, treatment modalities, local recurrence, metastasis, and prognosis were recorded.
  • There was no significant difference between the older patients and younger controls regarding tumour grading (p=0.068, Chi squared test), stage, and pathological diagnosis.
  • RESULTS: Six patients had bone and 14 had soft-tissue sarcomas.
  • Of the 14 soft-tissue sarcomas, 9 were malignant fibrous histiocytomas, 3 were myxofibrosarcomas, one was a liposarcoma and one an extraskeletal osteosarcoma; all were high grade except for 2 of the myxofibrosarcomas and the liposarcoma.
  • Of the 110 younger controls, 30 had bone and 80 had soft-tissue sarcomas; 44 were low grade and 66 were high grade.
  • Regarding bone versus soft-tissue sarcomas, the 5-year survival rate was not significantly different among older patients (0% vs 52%, p=0.068) or younger controls 61% vs 66%, p=0.863).
  • The difference was also not significant for older patients versus younger controls with bone sarcomas (0% vs 61%, p=0.284) or soft-tissue sarcomas (52% vs 66%, p=0.368), for older patients with high- versus low-grade sarcomas 17% vs 100%, p=0.314), for older patients with sarcomas located in the limbs versus the trunk (39% vs 38%, p=0.233), as well as for older patients versus younger controls with low-grade sarcomas (100% vs 92%, p=0.512) or high-grade sarcomas (17% vs 46%, p=0.269).
  • CONCLUSION: Survival rates tend to be lower in older patients with sarcomas, especially when the sarcoma is of bone and high grade.
  • [MeSH-major] Bone Neoplasms / mortality. Bone Neoplasms / pathology. Sarcoma / mortality. Sarcoma / pathology. Soft Tissue Neoplasms / mortality. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Cohort Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20427836.001).
  • [ISSN] 2309-4990
  • [Journal-full-title] Journal of orthopaedic surgery (Hong Kong)
  • [ISO-abbreviation] J Orthop Surg (Hong Kong)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Manoso MW, Frassica DA, Deune EG, Frassica FJ: Outcomes of re-excision after unplanned excisions of soft-tissue sarcomas. J Surg Oncol; 2005 Sep 1;91(3):153-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of re-excision after unplanned excisions of soft-tissue sarcomas.
  • BACKGROUND AND OBJECTIVES: Unplanned excisions of soft-tissue sarcomas of the extremities occur commonly.
  • Our goal was to evaluate the presence of residual disease, the treatment outcomes as they relate to local and distant recurrence and 5-year survival, and the limb functional outcomes in patients with unplanned sarcoma excision who were treated with re-excision and adjuvant therapy.
  • METHODS: Between 1993 and 1999, 42 patients presented to our institution after unplanned excision of soft-tissue sarcomas.
  • Univariate analysis showed that stage-III disease (American Joint Committee on Cancer classification of soft-tissue sarcomas), lesions below the fascia, a histologic high-grade, and the development of organ metastasis were statistically significant factors for mortality.
  • Stage-III disease also was significant for mortality on multivariate analysis.
  • Only stage-III disease was significant for the development of local recurrence.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Neoplasm, Residual / surgery. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Baltimore / epidemiology. Combined Modality Therapy. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Proportional Hazards Models. Reoperation. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 16118773.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Gupta A, Rao HK, Gupta S: The incidence of soft tissue sarcoma in Dakshina Kannada: study in a District Government Hospital. Indian J Surg; 2009 Feb;71(1):10-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The incidence of soft tissue sarcoma in Dakshina Kannada: study in a District Government Hospital.
  • BACKGROUND: We present a retrospective study depicting the incidence and outcome of soft tissue sarcomas (STSs) in patients admitted in a District Government Hospital situated in coastal belt of Southern India for a period of four and a half years.
  • METHODS: Histologically proven soft tissue STS patients admitted in Department of General Surgery in District Government Wenlock Hospital, Mangalore, from January 2002 to July 2007 were included in the study.
  • Ninety percent belonged to adolescents and adult age group.
  • Liposarcoma (18%) is the most common subtype followed by leiomyosarcoma, Ewings' sarcoma.
  • CONCLUSION: Majority of patients presenting to our institution in advanced stage of the disease, indicating ignorance, fear and reluctance for surgery; as well as economic constraints, that delay early detection and initiation of proper treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1317-29 [1634922.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1121-34 [8203453.001]
  • [Cites] Can J Surg. 1993 Apr;36(2):178-80 [8472231.001]
  • [Cites] Cancer Treat Res. 1997;91:9-29 [9286486.001]
  • [Cites] Virchows Arch. 2001 Aug;439(2):141-51 [11561754.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):8-9 [10030406.001]
  • [Cites] Verh Dtsch Ges Pathol. 1997;81:318-26 [9474886.001]
  • (PMID = 23133101.001).
  • [ISSN] 0972-2068
  • [Journal-full-title] The Indian journal of surgery
  • [ISO-abbreviation] Indian J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3452575
  • [Keywords] NOTNLM ; Dakshina Kannada / District Government Wenlock Hospital / Incidence / Soft tissue sarcoma
  •  go-up   go-down


22. Wang L, Tan MH: The natural history and prognosticative factors of adult extremity soft tissue sarcomas: an Asian perspective. Ann Acad Med Singapore; 2010 Oct;39(10):771-7
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history and prognosticative factors of adult extremity soft tissue sarcomas: an Asian perspective.
  • INTRODUCTION: We describe the natural history of Asian adult soft tissue sarcomas (STSs) in the extremities and predict prognosticative factors for local recurrence, metastasis and tumour-related death.
  • MATERIALS AND METHODS: Between January 1999 and May 2009, 67 adult patients with first presentation STSs of extremity sites underwent surgical treatment at a single institution.
  • On univariate analysis, high tumour grade and advanced stage (IIc to IV) were predictive of local recurrence and metastasis.
  • CONCLUSIONS: Asian adult extremity soft tissue sarcomas present late and are most commonly found in the thigh.
  • [MeSH-major] Extremities / physiopathology. Sarcoma. Soft Tissue Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Asia / epidemiology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21063637.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


23. Cahlon O, Spierer M, Brennan MF, Singer S, Alektiar KM: Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy. Cancer; 2008 Jun 15;112(12):2774-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy.
  • BACKGROUND: The purpose was to define the rate of local recurrence (LR) and identify prognostic factors for LR in patients with extremity soft-tissue sarcoma (STS) treated with limb-sparing surgery and a pathologically negative re-resection specimen without radiotherapy (RT).
  • METHODS: A review of the prospective sarcoma database identified 200 patients with primary, nonmetastatic, extremity STS treated with limb-sparing surgery between June 1982 and December 2002 who had a pathologically confirmed negative re-resection.
  • Factors associated with higher LR rates on univariate and multivariate analysis were older age, stage III presentation, and histology.
  • For patients with stage III the LR rate was 26% versus 7% for those with stage I/II (P<.001).
  • On multivariate analysis only age>or=50 (relative risk [RR] 3.3; P=.02) and stage III disease (RR 3.4; P=.01) remained significant predictors for LR.
  • When the cohort of patients was divided into 3 groups based on the number of risk factors present, the 5-year LRs were as follows: no risk factors (stage I/II and<50 years old) 4%, 1 risk factor (stage III or>or=50) 12%, and 2 risk factors (stage III and>or=50) 31% (P<.01).
  • Whereas the overall rate of local recurrence at 5 years was 9% for the entire cohort, patients with older age and/or stage III disease had a higher rate of LR.
  • [MeSH-major] Extremities / surgery. Neoplasm Recurrence, Local / pathology. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Disease-Free Survival. Feasibility Studies. Humans. Middle Aged. Radiotherapy, Adjuvant. Reoperation. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 American Cancer Society.
  • (PMID = 18429001.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Hwang S, Lefkowitz R, Landa J, Akin O, Schwartz LH, Cassie C, Healey JH, Alektiar KM, Panicek DM: Local changes in bone marrow at MRI after treatment of extremity soft tissue sarcoma. Skeletal Radiol; 2009 Jan;38(1):11-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local changes in bone marrow at MRI after treatment of extremity soft tissue sarcoma.
  • OBJECTIVE: To determine the prevalence and appearance of magnetic resonance imaging (MRI) signal changes that occur in local bone marrow after radiation therapy (RT) and/or chemotherapy for extremity soft tissue sarcoma (STS).
  • The marrow changes might represent an early stage of gelatinous transformation of marrow.
  • [MeSH-major] Bone Marrow / pathology. Magnetic Resonance Imaging / methods. Sarcoma / drug therapy. Sarcoma / radiotherapy. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Contrast Media. Disease Progression. Extremities. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1996 Mar;166(3):621-5 [8623638.001]
  • [Cites] AJR Am J Roentgenol. 1985 Jun;144(6):1131-5 [3873791.001]
  • [Cites] Radiology. 1995 May;195(2):413-7 [7724759.001]
  • [Cites] Cancer. 1978 Sep;42(3):1057-65 [100197.001]
  • [Cites] AJR Am J Roentgenol. 1990 Apr;154(4):745-50 [2107669.001]
  • [Cites] Radiographics. 1998 Sep-Oct;18(5):1125-36; quiz 1242-3 [9747611.001]
  • [Cites] AJR Am J Roentgenol. 1991 Jul;157(1):87-92 [1904679.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):56-65 [10632488.001]
  • [Cites] Radiology. 1994 Dec;193(3):859-64 [7972838.001]
  • [Cites] Radiology. 2002 Jan;222(1):179-83 [11756723.001]
  • [Cites] Radiology. 1995 Feb;194(2):537-43 [7824737.001]
  • (PMID = 18704399.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


25. Modritz D, Ladenstein R, Pötschger U, Amman G, Dieckmann K, Horcher E, Urban C, Meister B, Schmitt K, Jones R, Kaulfersch W, Haas H, Moser R, Stöllinger O, Peham M, Gadner H, Koscielniak E, Treuner J: Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study. Wien Klin Wochenschr; 2005 Mar;117(5-6):196-209
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for soft tissue sarcoma in childhood and adolescence. Austrian results within the CWS 96 study.
  • OBJECTIVE: The aim of the CWS 96 Study was to achieve an optimal treatment in children and adolescents with soft tissue sarcoma (STS) implementing a further refinement of risk-adapted allocation to chemotherapy, surgery and radiotherapy.
  • METHODS: Treatment stratification was based on tumour histology, TNM status, postsurgical stage, localisation and age.
  • [MeSH-major] Risk Assessment / methods. Sarcoma / mortality. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Austria / epidemiology. Child. Child, Preschool. Cohort Studies. Disease-Free Survival. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Prognosis. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Wien Klin Wochenschr. 2005 Mar;117(5-6):176-9 [15875755.001]
  • (PMID = 15875759.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


26. Ebeling P, Eisele L, Schuett P, Bauer S, Schuette J, Moritz T, Seeber S, Flasshove M: Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience. Onkologie; 2008 Feb;31(1-2):11-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
  • INTRODUCTION: Advanced stage/metastatic soft tissue sarcoma (STS) has a poor prognosis especially after failure of the established first-line treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Aged. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Leiomyosarcoma / drug therapy. Leiomyosarcoma / mortality. Leiomyosarcoma / pathology. Male. Middle Aged. Neoplasm Staging. Palliative Care. Retrospective Studies. Survival Analysis. Taxoids / administration & dosage. Taxoids / adverse effects. Uterine Neoplasms / drug therapy. Uterine Neoplasms / mortality. Uterine Neoplasms / pathology

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2008 Feb;31(1-2):6-8 [18268393.001]
  • (PMID = 18268394.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


27. Bache M, Kappler M, Wichmann H, Rot S, Hahnel A, Greither T, Said HM, Kotzsch M, Würl P, Taubert H, Vordermark D: Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC Cancer; 2010;10:132
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients.
  • However, only a few studies investigated the prognostic impact of expression of OPN in soft tissue sarcomas (STS) yet.
  • METHODS: This study is based on tumor and serum samples from 93 adult STS patients.
  • We investigated OPN protein levels in serum (n = 86) and tumor tissue (n = 80) by ELISA and OPN mRNA levels in tumor tissue (n = 68) by quantitative real-time PCR.
  • RESULTS: No correlation was found between OPN levels in serum and tumor tissue.
  • Moreover, an elevated OPN protein level in the serum was significantly associated with clinical parameters such as higher stage (p = 0.004), higher grade (p = 0.003), subtype (p = 0.002) and larger tumor size (p = 0.03).
  • OPN protein levels in the tumor tissue were associated with higher stage (p = 0.06), higher grade (p = 0.003), subtype (p = 0.07) and an increased rate of relapse (p = 0.02).
  • In addition, using a Cox's proportional hazards regression model, we found that an elevated OPN protein level in the serum and tumor tissue extracts is a significant negative prognostic factor for patients with STS.
  • CONCLUSION: Our data suggest OPN protein in serum as well as in tumor tissue extracts is an important prognostic factor for soft tissue sarcoma patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Osteopontin / metabolism. Sarcoma / metabolism. Soft Tissue Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Hypoxia / physiology. Humans. Middle Aged. Neoplasm Staging. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Dec;14(12):3419-27 [17896150.001]
  • [Cites] Oncogene. 2007 Nov 1;26(50):7170-4 [17525744.001]
  • [Cites] Cell Mol Biol Lett. 2008;13(1):11-9 [17952379.001]
  • [Cites] Cancer Metastasis Rev. 2008 Mar;27(1):103-18 [18049863.001]
  • [Cites] Curr Med Chem. 2008;15(4):322-38 [18288988.001]
  • [Cites] Head Neck. 2008 Jun;30(6):776-81 [18228527.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 Aug;134(8):909-17 [18210151.001]
  • [Cites] Lab Invest. 2008 Dec;88(12):1264-77 [18838962.001]
  • [Cites] Anticancer Res. 2008 Nov-Dec;28(6B):4105-10 [19192668.001]
  • [Cites] J Cell Physiol. 2000 Jul;184(1):118-30 [10825241.001]
  • [Cites] Cancer Lett. 2001 Sep 20;170(2):199-205 [11463499.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):668-74 [11764388.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] Curr Mol Med. 2001 Nov;1(5):621-32 [11899236.001]
  • [Cites] Lancet. 2002 Mar 16;359(9310):943-5 [11918915.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3417-27 [12067984.001]
  • [Cites] Virchows Arch. 2002 Oct;441(4):345-9 [12404059.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1098-104 [12631613.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1588-96 [15014008.001]
  • [Cites] Eur J Cancer. 1993;29A(15):2089-93 [8297645.001]
  • [Cites] Lab Invest. 1995 Jan;72(1):55-63 [7837791.001]
  • [Cites] Int J Cancer. 1998 Oct 23;79(5):502-8 [9761120.001]
  • [Cites] Br J Cancer. 2005 Aug 22;93(4):453-7 [16091764.001]
  • [Cites] Cancer Biol Ther. 2005 Jul;4(7):740-6 [15970685.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8019-27 [16299231.001]
  • [Cites] Cancer Biol Ther. 2005 Dec;4(12):1336-41 [16258259.001]
  • [Cites] Int J Cancer. 2006 May 1;118(9):2255-61 [16331611.001]
  • [Cites] Oncogene. 2006 Apr 6;25(15):2192-202 [16288209.001]
  • [Cites] BMC Cancer. 2006;6:207 [16911785.001]
  • [Cites] BMC Cancer. 2006;6:237 [17022822.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1481-7 [17056190.001]
  • [Cites] Expert Opin Ther Targets. 2007 Jan;11(1):81-90 [17150036.001]
  • [Cites] Cancer Lett. 2007 Mar 8;247(1):98-102 [16675104.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Feb;292(2):C919-26 [17005603.001]
  • [Cites] Radiother Oncol. 2007 Jun;83(3):389-97 [17499868.001]
  • [Cites] Oncogene. 2007 Sep 27;26(44):6361-71 [17452979.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):889-97 [17960616.001]
  • (PMID = 20377868.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  • [Other-IDs] NLM/ PMC2856551
  •  go-up   go-down


28. Mack LA, Crowe PJ, Yang JL, Schachar NS, Morris DG, Kurien EC, Temple CL, Lindsay RL, Magi E, DeHaas WG, Temple WJ: Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma. Ann Surg Oncol; 2005 Aug;12(8):646-53
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative chemoradiotherapy (modified Eilber protocol) provides maximum local control and minimal morbidity in patients with soft tissue sarcoma.
  • BACKGROUND: Local recurrence rates of 15% to 30% after treatment of soft tissue sarcoma (STS) are still common but unacceptable.
  • Although margin (P = .001) and stage (P = .035) were correlated, these were not significant on multivariate Cox regression analysis.
  • Risk factors for death included tumor stage (hazard ratio, 1.54; P = .001) and tumor grade (hazard ratio, 1.4; P = .02).
  • Three patients (4%) required reoperation for tissue loss, and eight patients (10.6%) developed minor wound complications.
  • [MeSH-major] Neoadjuvant Therapy / methods. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antibiotics, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Doxorubicin / administration & dosage. Female. Histiocytoma, Benign Fibrous / pathology. Histiocytoma, Benign Fibrous / surgery. Histiocytoma, Benign Fibrous / therapy. Humans. Leiomyosarcoma / pathology. Leiomyosarcoma / surgery. Leiomyosarcoma / therapy. Liposarcoma / pathology. Liposarcoma / surgery. Liposarcoma / therapy. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Radiotherapy Dosage. Radiotherapy, Adjuvant. Retrospective Studies


29. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol; 2009 Jul 1;27(19):3126-32
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
  • PURPOSE Given the importance of angiogenesis in soft tissue sarcoma (STS), pazopanib, an oral angiogenesis inhibitor that targets vascular endothelial growth factor receptor and platelet-derived growth factor receptor, was explored in patients with advanced STS.
  • A Simon two-stage design was applied (P1 = 40%; P0 = 20%; alpha = beta = .1) for each stratum.
  • The adipocytic STS stratum was closed after the first stage, given insufficient activity (PFR(12 weeks), five [26%] of19).
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Pyrimidines / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Sulfonamides / therapeutic use
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19451427.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Pyrimidines; 0 / Sulfonamides; 7RN5DR86CK / pazopanib
  •  go-up   go-down


30. Tateishi U, Yamaguchi U, Maeda T, Seki K, Terauchi T, Kawai A, Arai Y, Moriyama N, Kakizoe T: Staging performance of carbon-11 choline positron emission tomography/computed tomography in patients with bone and soft tissue sarcoma: comparison with conventional imaging. Cancer Sci; 2006 Oct;97(10):1125-8
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Staging performance of carbon-11 choline positron emission tomography/computed tomography in patients with bone and soft tissue sarcoma: comparison with conventional imaging.
  • The present study was conducted to compare the diagnostic accuracy between carbon-11 choline (11C-choline) positron emission tomography (PET)/computed tomography (CT) and conventional imaging for the staging of bone and soft tissue sarcomas.
  • Tumor stage was confirmed by histological examination and/or by an obvious progression in number and/or size of the lesions on follow-up examinations.
  • Reviewers examining both 11C-choline PET/CT and conventional imaging classified T stage in all patients.
  • Interpretation based on 11C-choline PET/CT, the Node (N) stage was correctly diagnosed in all patients, whereas the accuracy of conventional imaging in N stage was 63%.
  • Tumor Node Metastasis (TNM) stage was assessed correctly with 11C-choline PET/CT in 15 of 16 patients (94%) and with conventional imaging in eight of 16 patients (50%).
  • 11C-choline PET/CT is more accurate than conventional imaging regarding clinical staging of patients with bone and soft tissue sarcomas.
  • [MeSH-major] Bone Neoplasms / diagnosis. Choline. Sarcoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Carbon Radioisotopes. Female. Humans. Male. Middle Aged. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16925579.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; N91BDP6H0X / Choline
  •  go-up   go-down


31. Brady MS, Brown K, Patel A, Fisher C, Marx W: A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol; 2006 Aug;13(8):1123-9
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity.
  • BACKGROUND: Isolated limb infusion (ILI) is a minimally invasive technique of delivering regional chemotherapy in patients with advanced melanoma or soft tissue sarcoma of the limb.
  • METHODS: Eligible patients had American Joint Committee on Cancer stage IIIB or IIIC melanoma or unresectable soft tissue sarcoma of the limb.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / methods. Melanoma / drug therapy. Sarcoma / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Angiography. Dactinomycin / administration & dosage. Extremities. Female. Humans. Male. Melphalan / administration & dosage. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome


32. Merimsky O, Soyfer V, Kovner F, Bickels J, Issakov J, Flusser G, Meller I, Ofer O, Kollender Y: Limb sparing approach: adjuvant radiation therapy in adults with intermediate or high-grade limb soft tissue sarcoma. Radiother Oncol; 2005 Dec;77(3):295-300
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb sparing approach: adjuvant radiation therapy in adults with intermediate or high-grade limb soft tissue sarcoma.
  • BACKGROUND: Limb soft tissue sarcomas (STS) are currently treated with limb sparing surgery (LSS) followed by radiation therapy (RT).
  • PATIENTS AND METHODS: Between October 1994 and October 2002, 133 adult patients with intermediate or high-grade limb STS were approached by LSS+RT.
  • DFS and OS were influenced by disease stage II vs I, primary site in the upper limb vs lower limb, MPNST vs other types, induction therapy vs no induction, adequate resection vs marginal resection or involved margins, and good response to induction therapy vs bad response.
  • [MeSH-major] Limb Salvage. Sarcoma / radiotherapy. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Radiotherapy, Conformal. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16300847.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


33. Kepka L, DeLaney TF, Suit HD, Goldberg SI: Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys; 2005 Nov 1;63(3):852-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of radiation therapy for unresected soft-tissue sarcomas.
  • PURPOSE: Definitive radiotherapy is uncommonly used in the management of soft-tissue sarcoma (STS).
  • AJCC stage was related to the OS and DFS without statistically significant influence on LC.
  • In multivariate analysis, LC was related to total dose (p = 0.02), T size at radiotherapy (p = 0.003), and AJCC stage (p = 0.04); DFS was related to total dose (p = 0.007), T size at radiotherapy (p = 0.01), and AJCC stage (p < 0.0001); and OS was related to AJCC stage (p = 0.0001) and total dose (p = 0.002), but not to T size, at radiotherapy.
  • [MeSH-major] Sarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Radiation Injuries / etiology. Radiotherapy Dosage. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16199316.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Puhaindran ME, Steensma MR, Athanasian EA: Partial hand preservation for large soft tissue sarcomas of the hand. J Hand Surg Am; 2010 Feb;35(2):291-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Partial hand preservation for large soft tissue sarcomas of the hand.
  • In patients with large soft tissue sarcomas of the hand, partial hand preservation is extremely challenging for surgeons attempting a complete resection of the tumor with negative resection margins.
  • We conducted this review to examine the oncologic outcome, including local recurrence rate and patient overall survival, and functional outcome after resections for large soft tissue sarcomas with partial hand preservation.
  • METHODS: We performed a retrospective review of all patients with soft tissue sarcomas of the hand treated at our institution from 1995 to 2007.
  • Two patients had myxofibrosarcoma, 2 patients had synovial sarcoma, 2 patients had malignant fibrous histiocytoma, 1 patient had a malignant peripheral nerve sheath tumor, and 1 patient had a liposarcoma.
  • Two patients had American Joint Committee on Cancer stage 1b tumors, and 6 patients had American Joint Committee on Cancer stage 3 tumors.
  • CONCLUSIONS: Partial hand preservation is possible in selected patients with large soft tissue sarcomas of the hand, obtaining low local recurrence rates, good overall survival, and good functional outcome.
  • [MeSH-major] Hand / surgery. Limb Salvage / methods. Neoplasm Recurrence, Local / pathology. Sarcoma / diagnosis. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation / methods. Arm. Artificial Limbs. Child. Cohort Studies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prosthesis Fitting. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20141899.001).
  • [ISSN] 1531-6564
  • [Journal-full-title] The Journal of hand surgery
  • [ISO-abbreviation] J Hand Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Kawaguchi K, Oda Y, Saito T, Yamamoto H, Takahira T, Kobayashi C, Tamiya S, Tateishi N, Iwamoto Y, Tsuneyoshi M: DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol; 2006 Jan;19(1):106-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA hypermethylation status of multiple genes in soft tissue sarcomas.
  • To determine the clinicopathological significance of gene promoter methylation in soft tissue sarcomas, we examined the promoter methylation status of 10 tumor-related genes in 65 soft tissue sarcomas and 19 adjacent non-neoplastic tissues by methylation-specific PCR.
  • The methylation frequencies of tumor-related genes tested in soft tissue sarcomas were 17 (26%) for RASSF1A, 11 (17%) for DAP kinase, 10 (15%) for MGMT, nine (14%) for GSTP1, eight (12%) for PTEN, six (9%) for p16 and hMLH1, five (8%) for hMSH2, two (3%) for p14, and one (2%) for RB.
  • All those cases of soft tissue sarcoma that had MGMT methylation, with the exception of one case of malignant peripheral nerve sheath tumor, showed large tumor size (> or = 10 cm) or recurrence.
  • Moreover, eight of 10 cases with MGMT methylation revealed high American Joint Committee on Cancer stage.
  • In conclusion, although methylation of tumor-related genes was a relatively rare event in soft tissue sarcomas, methylation was tumor-specific.
  • Although our findings need to be extending to a large series, promoter methylation of tumor-related genes is likely to have an association with the pathogenesis of soft tissue sarcomas.
  • [MeSH-major] Biomarkers, Tumor / genetics. DNA Methylation. Sarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis Regulatory Proteins. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Carrier Proteins / genetics. Child. Child, Preschool. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Death-Associated Protein Kinases. Female. Glutathione S-Transferase pi / genetics. Humans. Immunohistochemistry. Infant. Male. Middle Aged. MutS Homolog 2 Protein / genetics. Nuclear Proteins / genetics. O(6)-Methylguanine-DNA Methyltransferase / analysis. O(6)-Methylguanine-DNA Methyltransferase / genetics. PTEN Phosphohydrolase / genetics. Polymerase Chain Reaction / methods. Promoter Regions, Genetic / genetics. Retinoblastoma Protein / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258501.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / RASSF1 protein, human; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


36. Potter BK, Adams SC, Qadir R, Pitcher JD, Temple HT: Fungating soft-tissue sarcomas. Treatment implications and prognostic importance of malignant ulceration. J Bone Joint Surg Am; 2009 Mar 1;91(3):567-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fungating soft-tissue sarcomas. Treatment implications and prognostic importance of malignant ulceration.
  • BACKGROUND: Several variables have been reported as being prognostic with regard to the outcomes of soft-tissue sarcomas.
  • Although the tumors are subjectively ominous, no prior study has been performed to evaluate the treatment or prognosis of fungating soft-tissue sarcomas.
  • METHODS: We performed a retrospective review of all soft-tissue sarcomas treated at our institution between 1989 and 2004 that had been followed for a minimum of two years or until the death of the patient.
  • Multivariate analysis demonstrated that disease stage, fungation, and a tumor size of > or = 10 cm were significant independent negative prognostic factors for disease-specific survival.
  • CONCLUSIONS: Malignant tumor ulceration is an independent predictor of a poor prognosis for patients with a high-grade soft-tissue sarcoma.
  • [MeSH-major] Sarcoma / pathology. Sarcoma / surgery. Ulcer / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19255216.001).
  • [ISSN] 1535-1386
  • [Journal-full-title] The Journal of bone and joint surgery. American volume
  • [ISO-abbreviation] J Bone Joint Surg Am
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Mankin HJ, Hornicek FJ: Diagnosis, classification, and management of soft tissue sarcomas. Cancer Control; 2005 Jan-Feb;12(1):5-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis, classification, and management of soft tissue sarcomas.
  • BACKGROUND: Soft tissue sarcomas are challenging to oncologists due to their unique character, the infrequency of their occurrence, and the difficulties in predicting outcomes.
  • METHODS: The various types of soft tissue tumors are defined, and the statistics for the Orthopaedic Oncology Group in relation to them are reviewed and compared with literature references.
  • Outcome was affected by patient age, tumor anatomic site, tumor stage, and a history of recurrence.
  • [MeSH-major] Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Fibrosarcoma / diagnosis. Fibrosarcoma / therapy. Histiocytoma, Benign Fibrous / diagnosis. Histiocytoma, Benign Fibrous / therapy. Humans. Leiomyosarcoma / diagnosis. Leiomyosarcoma / therapy. Liposarcoma / diagnosis. Liposarcoma / therapy. Male. Middle Aged. Neoplasm Staging / methods. Neurofibrosarcoma / diagnosis. Neurofibrosarcoma / therapy. Outcome Assessment (Health Care). Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Sarcoma, Clear Cell / diagnosis. Sarcoma, Clear Cell / therapy. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / therapy. Survival Analysis

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668648.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 205
  •  go-up   go-down


38. Kim B, Chen YL, Kirsch DG, Goldberg SI, Kobayashi W, Kung JH, Wolfgang JA, Doppke K, Rosenberg AE, Nielsen GP, Raskin KA, Springfield DS, Schwab JH, Gebhardt MC, Yoon SS, Hornicek FJ, DeLaney TF: An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. Int J Radiat Oncol Biol Phys; 2010 Jul 1;77(3):843-50
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control.
  • PURPOSE: There is little information on the appropriate three-dimensional (3D) preoperative radiotherapy (XRT) volume for extremity soft-tissue sarcomas (STS).
  • METHODS AND MATERIALS: We analyzed the 56 patients who underwent computed tomography-planned XRT for Stage I to III extremity STS between June 2000 and December 2006.
  • [MeSH-major] Extremities. Sarcoma / radiotherapy. Soft Tissue Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Humans. Male. Middle Aged. Postoperative Complications / surgery. Preoperative Care. Radiotherapy Dosage. Treatment Failure. Tumor Burden / radiation effects. Young Adult

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20005638.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Bhurgri Y, Bhurgri H, Pervez S, Kayani N, Usman A, Bashir I, Bhurgri A, Hasan SH, Zaidi SM: Epidemiology of soft tissue sarcomas in Karachi South, Pakistan (1995-7). Asian Pac J Cancer Prev; 2008 Oct-Dec;9(4):709-14
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of soft tissue sarcomas in Karachi South, Pakistan (1995-7).
  • INTRODUCTION: The present study was conducted with the objective of examining epidemiological characteristics of soft tissue sarcomas (STSs) in Karachi.
  • CONCLUSION: Karachi falls into a high risk region for STS, observed in a relatively younger population, with a male predominance, high frequency of rhabdomyosarcoma and advanced stage at diagnosis.
  • [MeSH-major] Sarcoma / epidemiology. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Developing Countries. Female. Humans. Male. Middle Aged. Neoplasm Staging. Pakistan / epidemiology. Prevalence. Prognosis. Registries. Retrospective Studies. Sex Distribution. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19256764.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


40. Sun L, Wu LY, Li XG, Bai P, Zhang HT: [Clinical characterization of vulvar epithelioid sarcoma]. Zhonghua Zhong Liu Za Zhi; 2010 Dec;32(12):935-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characterization of vulvar epithelioid sarcoma].
  • OBJECTIVE: Vulvar epithelioid sarcoma is a rare, undifferentiated soft-tissue sarcoma, with a high rate of local relapse, regional nodal spread and distant metastases.
  • METHODS: We studied the clinicopathologic features of 20 cases of vulvar epithelioid sarcoma, of which 4 cases were admitted to our hospital from 1999 to 2009.
  • Survival of the early stage (I-II) patients was significantly longer than those in the advanced stage (III-IV) (median, 21 vs. 6 months, P < 0.01).
  • Radical local excision with adequate margin (at least 2 cm) and bilateral inguinofemoral lymphadenectomy is effective for the treatment of vulvar epithelioid sarcoma.
  • [MeSH-major] Sarcoma / pathology. Sarcoma / surgery. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Keratins / metabolism. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Mucin-1 / metabolism. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Vimentin / metabolism. Vulva / surgery. Young Adult


41. Tanaka K, Kawamoto H, Saito I, Yoshimura K, Fukuda H, Iwamoto Y: Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304. Jpn J Clin Oncol; 2009 Apr;39(4):271-3
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade soft-tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304.
  • This phase II clinical trial aims to evaluate the efficacies and toxicities of pre- and postoperative chemotherapy with adriamycin plus ifosfamide on the patients with soft-tissue high-grade sarcomas.
  • Patients who have operable, non-round cell soft-tissue sarcomas [French Federation of Cancer Center (FNCLCC) Grades 2 and 3] arising in the extremities [T2bN0M0, i.e.
  • American Joint Committee on Cancer (AJCC) stage III] are treated by three courses of preoperative chemotherapy consisting of adriamycin and ifosfamide followed by complete resection and additional two courses of the same chemotherapy regimen.
  • The Bone and Soft Tissue Tumor Study Group (BSTTSG) in the Japan Clinical Oncology Group (JCOG) including 26 specialized institutes will accrue 75 patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / administration & dosage. Ifosfamide / administration & dosage. Sarcoma / drug therapy
  • [MeSH-minor] Adult. Disease-Free Survival. Extremities. Feasibility Studies. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Postoperative Care. Preoperative Care

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19155282.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


42. Evans SM, Fraker D, Hahn SM, Gleason K, Jenkins WT, Jenkins K, Hwang WT, Zhang P, Mick R, Koch CJ: EF5 binding and clinical outcome in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys; 2006 Mar 1;64(3):922-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EF5 binding and clinical outcome in human soft tissue sarcomas.
  • PURPOSE: To study the 2-nitroimidazole agent EF5 as a surrogate for measuring hypoxia in a series of patients with soft tissue sarcomas, and to determine whether hypoxia measured with this technique was associated with patient outcome.
  • METHODS AND MATERIALS: Patients with soft tissue sarcomas of the head and neck, extremity, trunk, or retroperitoneum for whom surgical excision was the initial treatment of choice, were given 21 mg/kg EF5 24-48 hours before surgery.
  • High-grade and -stage de novo tumors had higher levels of EF5 binding compared with low-grade and -stage tumors.
  • [MeSH-major] Cell Hypoxia / physiology. Etanidazole / analogs & derivatives. Hydrocarbons, Fluorinated / metabolism. Indicators and Reagents / metabolism. Neoplasm Recurrence, Local / metabolism. Sarcoma / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458778.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01-RR00040; United States / NCI NIH HHS / CA / R01 CA 75285
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide; 0 / Hydrocarbons, Fluorinated; 0 / Indicators and Reagents; 30DKA3Q1HL / Etanidazole
  •  go-up   go-down


43. Novais EN, Demiralp B, Alderete J, Larson MC, Rose PS, Sim FH: Do surgical margin and local recurrence influence survival in soft tissue sarcomas? Clin Orthop Relat Res; 2010 Nov;468(11):3003-11
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do surgical margin and local recurrence influence survival in soft tissue sarcomas?
  • BACKGROUND: Established prognostic factors influencing survival in soft tissue sarcomas include tumor stage, histopathologic grade, size, depth, and anatomic site.
  • QUESTIONS/PURPOSES: We explored the impact of microscopic margin on local recurrence, metastasis, and overall survival in patients with intermediate- to high-grade soft tissue sarcomas of the extremities.
  • METHODS: We retrospectively reviewed the medical records of 248 patients who had soft tissue sarcomas of the extremities treated surgically from 1995 to 2008.
  • In addition to surgical margin, developing metastasis, tumor response of less than 90% necrosis, high histopathologic grade, high AJCC stage (Stage III), increasing age, and male gender were associated with decreased overall survival.
  • CONCLUSIONS: Microscopic surgical margin and local recurrence after surgical treatment should be included as risk factors predicting decreased overall survival for intermediate- to high-grade soft tissue sarcomas of the extremities.
  • [MeSH-major] Neoplasm Recurrence, Local / mortality. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Extremities. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Minnesota / epidemiology. Neoplasm Staging. Proportional Hazards Models. Registries. Retrospective Studies. Risk Assessment. Risk Factors. Survival Rate. Time Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2000 Apr;36(6):710-6 [10762742.001]
  • [Cites] Ann Surg. 2003 Feb;237(2):218-26 [12560780.001]
  • [Cites] Acta Orthop Scand Suppl. 2001 Feb;72(300):1-31 [11381580.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • [Cites] J Surg Oncol. 1997 Oct;66(2):81-7 [9354161.001]
  • [Cites] Arch Surg. 1999 Feb;134(2):190-4 [10025462.001]
  • [Cites] Aust N Z J Surg. 1999 May;69(5):344-9 [10353548.001]
  • [Cites] Semin Radiat Oncol. 1999 Oct;9(4):307-14 [10516378.001]
  • [Cites] Semin Radiat Oncol. 1999 Oct;9(4):369-77 [10516384.001]
  • [Cites] ANZ J Surg. 2006 Mar;76(3):104-9 [16626341.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1583-90 [17260106.001]
  • [Cites] Ann Surg Oncol. 2007 May;14(5):1528-9 [17295083.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Clin Oncol. 1983 Nov;1(11):710-9 [6668489.001]
  • [Cites] Ann Surg. 1987 Apr;205(4):331-9 [3566371.001]
  • [Cites] Arch Surg. 1987 Nov;122(11):1289-93 [3314794.001]
  • [Cites] Semin Surg Oncol. 1988;4(1):38-44 [2832924.001]
  • [Cites] J Clin Oncol. 1988 Sep;6(9):1491-500 [3047339.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1317-29 [1634922.001]
  • [Cites] Clin Orthop Relat Res. 1993 Apr;(289):73-80 [8472434.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1230-8 [8339214.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1652-9 [8156492.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):646-52 [9053489.001]
  • [Cites] J Bone Joint Surg Br. 1997 Jul;79(4):553-7 [9250737.001]
  • [Cites] Clin Orthop Relat Res. 2001 Jun;(387):191-9 [11400883.001]
  • [Cites] J Bone Joint Surg Br. 2001 Nov;83(8):1149-55 [11764430.001]
  • [Cites] Ann Surg. 2002 Mar;235(3):424-34 [11882765.001]
  • [Cites] Acta Orthop Scand. 2000 Oct;71(5):488-95 [11186407.001]
  • (PMID = 20645035.001).
  • [ISSN] 1528-1132
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2947688
  •  go-up   go-down


44. Al-Refaie WB, Andtbacka RH, Ensor J, Pisters PW, Ellis TL, Shrout A, Hunt KK, Cormier JN, Pollock RE, Feig BW: Lymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomas. Cancer; 2008 Apr 15;112(8):1821-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomas.
  • BACKGROUND: Previous studies have suggested that the prognosis in patients with extremity soft-tissue sarcomas (ESTS) with isolated lymph node (LN) metastases (stage IV) is comparable to that of patients with high-risk ESTS without metastases (stage III).
  • CONCLUSIONS: Patients with isolated regional lymph node metastases who are treated with aggressive approaches, including regional LN dissection, may experience prolonged survival similar to that which more closely approximates the survival seen in patients with stage III disease (5-year survival rate, 50%) rather than the survival seen in patients with stage IV disease (5-year survival rate, 25%).
  • [MeSH-major] Lower Extremity / pathology. Lymph Node Excision / methods. Lymphatic Metastasis / pathology. Sarcoma / secondary. Soft Tissue Neoplasms / secondary. Upper Extremity / pathology
  • [MeSH-minor] Actuarial Analysis. Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Histiocytoma, Malignant Fibrous / secondary. Histiocytoma, Malignant Fibrous / surgery. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18306370.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Oda Y, Saito T, Tateishi N, Ohishi Y, Tamiya S, Yamamoto H, Yokoyama R, Uchiumi T, Iwamoto Y, Kuwano M, Tsuneyoshi M: ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas. Int J Cancer; 2005 May 10;114(6):854-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ATP-binding cassette superfamily transporter gene expression in human soft tissue sarcomas.
  • However, their expression levels and distribution within soft tissue sarcomas remain controversial.
  • In 86 cases of surgically resected soft tissue sarcoma, intrinsic mRNA levels of MDR1, MRP1, MRP2 and MRP3 were assessed using a quantitative reverse transcriptase-PCR (RT-PCR) method.
  • P-gp expression was significantly correlated with large tumor size (> or =5 cm, p=0.041) and high AJCC stage (stages III and IV) (p=0.0365).
  • Our results suggest that MDR1/P-gp expression may have an important role to play in tumor progression in the cases of soft tissue sarcoma, and p53 may be one of the active regulators of the MDR1 transcript.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. ATP-Binding Cassette Transporters / genetics. Drug Resistance, Multiple. Gene Expression Regulation, Neoplastic. Genes, p53. Sarcoma / drug therapy. Sarcoma / genetics
  • [MeSH-minor] Adolescent. Adult. Disease Progression. Drug Resistance, Neoplasm / genetics. Female. Gene Expression Profiling. Humans. Immunohistochemistry. Male. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15609299.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


46. Delaney TF, Kepka L, Goldberg SI, Hornicek FJ, Gebhardt MC, Yoon SS, Springfield DS, Raskin KA, Harmon DC, Kirsch DG, Mankin HJ, Rosenberg AE, Nielsen GP, Suit HD: Radiation therapy for control of soft-tissue sarcomas resected with positive margins. Int J Radiat Oncol Biol Phys; 2007 Apr 1;67(5):1460-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation therapy for control of soft-tissue sarcomas resected with positive margins.
  • PURPOSE: Positive margins (PM) remain after surgery in some soft-tissue sarcoma (STS) patients.
  • Other known prognostic factors, including grade, stage, size, and age (>50), also significantly influenced OS.
  • [MeSH-major] Sarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Cause of Death. Child. Female. Humans. Male. Middle Aged. Neoplasm, Residual. Radiotherapy Dosage. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17394945.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Germain MA, Bonvalot S, Rimareix F, Missana CM: [Locally advanced soft-tissue sarcomas. An innovating triad to avoid amputation: isolated limb perfusion, TNFalpha, and free microsurgical flap]. Bull Acad Natl Med; 2010 Jan;194(1):51-65; discussion 65-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locally advanced soft-tissue sarcomas. An innovating triad to avoid amputation: isolated limb perfusion, TNFalpha, and free microsurgical flap].
  • We retrospectively studied the benefits of isolated limb perfusion combined with TNFalpha administration and free flap reconstruction in locally advanced soft-tissue sarcomas of the limbs.
  • Between 2000 and 2008, we treated 37 patients (22 women and 15 men) with locally advanced soft tissue sarcomas.
  • Sarcoma excision was combined with a complementary procedure in 10 patients (vascular graft or nerve anastomosis).
  • Three major improvements were made in recent years, namely isolated limb perfusion, TNFalpha administration, and free flap reconstruction two months after resection of residual sarcoma.
  • Tumor excision was stage R0 in 29 cases (clean margins), R1 in 7 cases (microscopic residue), and R2 in one case (macroscopic residue).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Extremities / surgery. Sarcoma / drug therapy. Sarcoma / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Male. Middle Aged. Muscle, Skeletal / transplantation. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasms, Radiation-Induced / drug therapy. Neoplasms, Radiation-Induced / surgery. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / surgery. Radiotherapy, Adjuvant. Reconstructive Surgical Procedures. Reoperation. Retrospective Studies. Skin Transplantation. Surgical Flaps. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20669559.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


48. Khoury JD, Coffin CM, Spunt SL, Anderson JR, Meyer WH, Parham DM: Grading of nonrhabdomyosarcoma soft tissue sarcoma in children and adolescents: a comparison of parameters used for the Fédération Nationale des Centers de Lutte Contre le Cancer and Pediatric Oncology Group Systems. Cancer; 2010 May 1;116(9):2266-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grading of nonrhabdomyosarcoma soft tissue sarcoma in children and adolescents: a comparison of parameters used for the Fédération Nationale des Centers de Lutte Contre le Cancer and Pediatric Oncology Group Systems.
  • BACKGROUND: Two systems for grading soft tissue sarcoma are widely used currently: the National Cancer Institute (NCI) and the Fédération Nationale des Centers de Lutte Contre le Cancer (FNCLCC) systems.
  • Both were developed using cohorts of predominantly adult patients.
  • The Pediatric Oncology Group (POG) system, based on the NCI system, was adapted for grading pediatric nonrhabdomyosarcoma soft tissue sarcoma (NRSTS).
  • RESULTS: As expected, stage and tumor sizes were predictive of EFS (P < .001).

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1219 [10561182.001]
  • [Cites] Oncologist. 2008 Jun;13(6):668-78 [18586922.001]
  • [Cites] Cancer. 2001 May 15;91(10):1914-26 [11346874.001]
  • [Cites] Cancer. 2003 May 15;97(10):2530-43 [12733153.001]
  • [Cites] Am J Surg Pathol. 1982 Oct;6(7):655-63 [7180965.001]
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):37-42 [6693192.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):172-7 [3940616.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1437-51 [2646010.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1317-29 [1634922.001]
  • [Cites] Mod Pathol. 1995 Sep;8(7):705-10 [8539226.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):869-77 [8622035.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1679-89 [8622088.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Med Pediatr Oncol. 1998 Apr;30(4):201-9 [9473754.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4031-8 [15767644.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4021-30 [15767645.001]
  • [Cites] Histopathology. 2006 Jan;48(1):42-50 [16359536.001]
  • [Cites] Lab Invest. 2007 May;87(5):403-8 [17401434.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3697-705 [10577841.001]
  • (PMID = 20166208.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA98413; None / None / / U10 CA098413-04; United States / NCI NIH HHS / CA / U10 CA098413-04; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA023099-310016; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P01 CA023099-310016; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA098543-01; United States / NCI NIH HHS / CA / CA023099; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS163772; NLM/ PMC2987713
  •  go-up   go-down


49. Kim JI, Suh JT, Choi KU, Kang HJ, Shin DH, Lee IS, Moon TY, Kim WT: Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations. Hum Pathol; 2009 Jul;40(7):934-41
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of O6-methylguanine-DNA methyltransferase in soft tissue sarcomas: association with K-ras mutations.
  • Sixty-two patients with soft tissue sarcomas were analyzed with regard to the status of O(6)-methylguanine-DNA methyltransferase protein expression status using immunohistochemistry and promoter hypermethylation of the MGMT gene using methylation-specific PCR.
  • A loss of O(6)-methylguanine-DNA methyltransferase expression was noted in 20 (32.3%) cases of 62 total soft tissue sarcomas.
  • Loss of O(6)-methylguanine-DNA methyltransferase expression and MGMT promoter hypermethylation showed a significant association with high American Joint Committee on Cancer stage, high French Federation of Cancer Centers grade, and aggressive behavior.
  • [MeSH-major] Genes, ras / genetics. O(6)-Methylguanine-DNA Methyltransferase / antagonists & inhibitors. Sarcoma / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. DNA Methylation. Female. Gene Expression Regulation, Neoplastic. Humans. Infant. Male. Middle Aged. Mutation. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19356788.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


50. Mu JW, Xing XZ, Li J, Cheng GY, Sun KL, He J: [Primary soft tissue sarcomas of mediastinum: experience in 22 cases from a single institution]. Zhonghua Yi Xue Za Zhi; 2008 Feb 19;88(7):468-70
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary soft tissue sarcomas of mediastinum: experience in 22 cases from a single institution].
  • OBJECTIVE: To assess the presentation, imaging features, and prognostic factors of primary soft tissue sarcoma of mediastinum.
  • METHODS: The clinical data of 22 patients with primary soft tissue sarcoma of mediastinum, 12 males and 10 females, aged 46 (28-69), hospitalized over 27 years were retrospectively reviewed, focusing on the clinical presentations, preoperative diagnosis, imaging features, immunohistochemical studies, treatment, and survival.
  • The 5-year survival rate of the patients with lesions at high grade and stage III were 38.2% and 38.2% respectively, both lower, though not significantly, than those of lesions at low grade and stage I (60% and 60% respectively, both P =0.317).
  • CONCLUSION: Tumor size and character of resection are important prognostic factors for primary soft tissue sarcoma of mediastinum.
  • [MeSH-major] Mediastinal Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. Antigens, Differentiation, Myelomonocytic / analysis. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Mediastinum / pathology. Mediastinum / surgery. Middle Aged. Retrospective Studies. Survival Analysis. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18642788.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / Vimentin
  •  go-up   go-down


51. MacDermed DM, Miller LL, Peabody TD, Simon MA, Luu HH, Haydon RC, Montag AG, Undevia SD, Connell PP: Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys; 2010 Mar 15;76(4):1147-53
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy.
  • PURPOSE: Various neoadjuvant approaches have been evaluated for the treatment of locally advanced soft-tissue sarcomas.
  • METHODS AND MATERIALS: We treated 34 patients (28 Stage III and 6 Stage IV) with locally advanced soft-tissue sarcomas of an extremity between 1995 and 2008.
  • The 5-year survival rate was 42.3% for all patients and 45.2% for Stage III patients.
  • The 5-year freedom-from-distant metastasis rate was 53.4% (Stage IV patients excluded), and freedom from distant metastasis was superior if treatment-induced tumor necrosis was 90% or greater (84.6% vs. 19.9%, p = 0.02).

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Cancer. 1993 Jun 1;71(11):3685-9 [8490918.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):259-65 [8407399.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):172-7 [3940616.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2659-67 [3995476.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2579-84 [6372980.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):908-15 [14624787.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27 [12829150.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3203-9 [11432887.001]
  • [Cites] Eur J Cancer. 2001 Jun;37(9):1096-103 [11378339.001]
  • [Cites] Cancer. 2001 May 15;91(10):1914-26 [11346874.001]
  • [Cites] Cancer. 1995 May 1;75(9):2299-306 [7712441.001]
  • [Cites] Cancer. 2008 Jun;112(11):2432-9 [18348295.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3144-50 [17634494.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):619-25 [16446334.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):646-53 [15965732.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1667-72 [15520069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):563-72 [9806516.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):504-14 [9344316.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):977-85 [7607972.001]
  • (PMID = 19577863.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA124557-01A1; United States / NCI NIH HHS / CA / R21 CA124557; United States / NCI NIH HHS / CA / R21 CA124557-01A1
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Other-IDs] NLM/ NIHMS230212; NLM/ PMC2931332
  •  go-up   go-down


52. Landa J, Schwartz LH: Contemporary imaging in sarcoma. Oncologist; 2009 Oct;14(10):1021-38
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contemporary imaging in sarcoma.
  • It is imperative to obtain appropriate imaging of these tumors in order to adequately assess, characterize, and stage bone and soft tissue sarcomas.
  • [MeSH-major] Bone Neoplasms / diagnosis. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals. Sarcoma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Metastasis / diagnosis. Neoplasm Staging. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789392.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


53. Dudeck O, Zeile M, Pink D, Pech M, Tunn PU, Reichardt P, Ludwig WD, Hamm B: Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging; 2008 May;27(5):1109-13
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas.
  • PURPOSE: To determine if diffusion-weighted imaging (DWI) can be used as a surrogate marker of tumor response to anticancer therapy in patients with soft-tissue sarcomas.
  • MATERIALS AND METHODS: Magnetic resonance imaging (MRI) including echo-planar DWI sequences was performed prospectively in 23 consecutive patients with soft-tissue sarcomas before and after initiation of regional or systemic chemotherapy.
  • CONCLUSION: DWI can be used as a supplement to morphologic imaging for the evaluation of tumor response to anticancer therapy in patients with soft-tissue sarcomas.
  • As cellular changes are expected to precede morphologic changes in treated tumors, DWI performed at an early stage of fractionated therapy may provide unique prognostic information of its effectiveness.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Sarcoma / therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Contrast Media. Female. Gadolinium DTPA. Humans. Male. Middle Aged. Phantoms, Imaging. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18425832.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


54. Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, Munzert G, Fritsch H, Hanft G, Aerts C, Rapion J, Allgeier A, Bogaerts J, Lacombe D: Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer; 2010 Aug;46(12):2206-15
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI).
  • PATIENTS AND METHODS: Patients with advanced head and neck, breast and ovarian cancer, soft tissue sarcoma and melanoma were selected according to protocol-defined general and tumour-specific criteria.
  • The study was based on a Simon two-stage design, with 12 patients entering in stage 1 and additional 25 patients to be entered in case of at least one response in the first stage.
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Feasibility Studies. Female. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / metabolism. Humans. Infusions, Intravenous. Male. Melanoma / drug therapy. Melanoma / metabolism. Middle Aged. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / metabolism. Patient Compliance. Sarcoma / drug therapy. Sarcoma / metabolism. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20471824.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BI 2536; 0 / Pteridines
  •  go-up   go-down


55. Barreto-Andrade JC, Medina-Franco H: Serum albumin is an independent prognostic factor for survival in soft tissue sarcomas. Rev Invest Clin; 2009 May-Jun;61(3):198-204
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum albumin is an independent prognostic factor for survival in soft tissue sarcomas.
  • BACKGROUND: Soft tissue sarcomas are rare tumors with a wide clinical spectrum.
  • METHODS: We analyzed a group of 61 patients with soft tissue sarcomas.
  • Adverse prognostic factors for overall survival in multivariate analysis were advanced stage, high tumor grade, irresecability, and serum albumin.
  • CONCLUSIONS: Besides the usual tumor related prognostic factors, such as grade and stage, patient related factors, such as performance status and surgical risk should be considered when predicting survival.
  • [MeSH-major] Sarcoma / blood. Serum Albumin / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers. Cachexia / blood. Cachexia / etiology. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Liposarcoma / blood. Liposarcoma / mortality. Liposarcoma / therapy. Male. Mexico / epidemiology. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736808.001).
  • [ISSN] 0034-8376
  • [Journal-full-title] Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
  • [ISO-abbreviation] Rev. Invest. Clin.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Serum Albumin
  •  go-up   go-down


56. Van Damme JP, Schmitz S, Machiels JP, Galant C, Grégoire V, Lengelé B, Hamoir M: Prognostic factors and assessment of staging systems for head and neck soft tissue sarcomas in adults. Eur J Surg Oncol; 2010 Jul;36(7):684-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors and assessment of staging systems for head and neck soft tissue sarcomas in adults.
  • OBJECTIVES: The primary objectives of this study were to analyse the outcome of patients diagnosed with head and neck soft tissue sarcomas (HNSTS) and to identify relevant prognostic factors.
  • METHODS: From 07/1988 to 01/2008, the charts of 42 adult patients were retrospectively reviewed.
  • On univariate analysis, statistically significant prognostic factors were for OS, distant or lymph node metastasis at diagnosis (p=0.032), for DFS, margins after surgery (p=0.007), for DSS, regional or distant metastasis at diagnosis (p=0.002), initial AJCC and MSKCC stage (p=0.018 and p=0.048) and margins after surgery (p=0.042).
  • On multivariate analysis, margins remained statistically significant for DFS (p=0.039) when there was a trend with the initial AJCC stage (p=0.054) for OS.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Sarcoma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Risk Assessment. Risk Factors

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20542404.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  •  go-up   go-down


57. Masciullo V, Berardengo E, Boglione A, Sgambato A, Bernardi A, Forni M, Linari A, Cito L, Scambia G, Comandone A, Giordano A: The retinoblastoma family member pRb2/p130 is an independent predictor of survival in human soft tissue sarcomas. Clin Cancer Res; 2008 Aug 1;14(15):4775-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The retinoblastoma family member pRb2/p130 is an independent predictor of survival in human soft tissue sarcomas.
  • We sought to evaluate pRb2/p130 protein expression and its clinical effect in patients affected with soft tissue sarcomas (STS).
  • In multivariate analysis, reduced pRb2/p130 expression was confirmed to be an independent predictor of shorter OS when considered together with tumor stage and grading (risk ratio, 7.893; confidence interval, 1.618-38.509; P = 0.011).
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Retinoblastoma-Like Protein p130 / biosynthesis. Retinoblastoma-Like Protein p130 / physiology. Sarcoma / metabolism. Sarcoma / mortality. Soft Tissue Neoplasms / metabolism. Soft Tissue Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Humans. Immunohistochemistry. Middle Aged. Models, Biological. Multivariate Analysis. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Retinoblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676747.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Retinoblastoma-Like Protein p130
  •  go-up   go-down


58. Bannasch H, Haivas I, Momeni A, Stark GB: Oncosurgical and reconstructive concepts in the treatment of soft tissue sarcomas: a retrospective analysis. Arch Orthop Trauma Surg; 2009 Jan;129(1):43-9
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncosurgical and reconstructive concepts in the treatment of soft tissue sarcomas: a retrospective analysis.
  • BACKGROUND: Patients with soft tissue sarcomas are initially treated in community hospitals and in the private practice setting in the majority of cases.
  • Kaplan-Meier analysis displayed significant differences in overall survival rate depending on disease stage upon initial presentation.
  • [MeSH-major] Reconstructive Surgical Procedures / methods. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18210141.001).
  • [ISSN] 1434-3916
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Huber GF, Matthews TW, Dort JC: Soft-tissue sarcomas of the head and neck: a retrospective analysis of the Alberta experience 1974 to 1999. Laryngoscope; 2006 May;116(5):780-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue sarcomas of the head and neck: a retrospective analysis of the Alberta experience 1974 to 1999.
  • BACKGROUND: Soft-tissue sarcomas (STS) of the head and neck constitute a heterogeneous group of rare malignant tumors occurring in an uncommon site.
  • With use of a Cox proportional-hazards model, tumor stage and grade were important prognostic factors affecting survival.
  • [MeSH-major] Cause of Death. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / pathology. Sarcoma / epidemiology. Sarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Alberta / epidemiology. Biopsy, Needle. Combined Modality Therapy. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Proportional Hazards Models. Registries. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16652087.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Kepka L, Suit HD, Goldberg SI, Rosenberg AE, Gebhardt MC, Hornicek FJ, Delaney TF: Results of radiation therapy performed after unplanned surgery (without re-excision) for soft tissue sarcomas. J Surg Oncol; 2005 Oct 1;92(1):39-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of radiation therapy performed after unplanned surgery (without re-excision) for soft tissue sarcomas.
  • BACKGROUND AND PURPOSE: For soft tissue sarcomas (STS), some patients undergo an "unplanned surgery," non-oncologic resection for presumed benign tumor.
  • Tumor characteristics: location, lower extremity (63%), upper extremity (27%), other (10%); median tumor size, 5 cm; grade-G1 (19%), G2 (49%), G3 (32%); AJCC stage (2002)-I (19%), II (54%), III (27%).
  • Depth in the relation to the fascia, tumor size, and AJCC stage significantly influenced local recurrence- and distant metastasis-free survival.
  • [MeSH-major] Sarcoma / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Radiotherapy / adverse effects. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Treatment Failure

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16180232.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. García-Aceituno L, Villarreal-Garza C, Perfecto M, León-Rodríguez E: Retroperitoneal soft tissue sarcomas: experience at a single institution in Mexico. World J Surg; 2010 Jul;34(7):1511-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal soft tissue sarcomas: experience at a single institution in Mexico.
  • BACKGROUND: Retroperitoneal soft tissue sarcomas (RSTS) are a rare and uncommon entity with a poor 5-year overall survival (OS) of approximately 50%, even though they rarely metastasize.
  • Variables analyzed were age, sex, histological type, TNM stage, tumor size, grade of differentiation, and treatment (surgery, chemotherapy only, radiotherapy only, adjuvant radiotherapy, and best supportive care).
  • Overall survival, recurrence-free survival (RFS), cancer-specific survival (CSS), and survival comparison by stage, grade, and type of resection were analyzed.
  • CONCLUSIONS: Incomplete surgical resection, unresectable disease, high histological grade, and advanced TNM stage are associated with a poor survival in patients with RSTS.
  • [MeSH-major] Retroperitoneal Neoplasms / mortality. Sarcoma / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Sarcoma. 2000;4(1-2):17-26 [18521430.001]
  • [Cites] Cancer. 2006 Jul 15;107(2):371-9 [16752414.001]
  • [Cites] Tumori. 2008 Jul-Aug;94(4):497-504 [18822685.001]
  • [Cites] Curr Opin Oncol. 2002 Jul;14(4):400-5 [12130924.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):31-7 [19047280.001]
  • [Cites] Sarcoma. 2001;5(1):5-8 [18521302.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):244-50 [14745333.001]
  • [Cites] Eur J Surg Oncol. 2009 Sep;35(9):986-93 [19138832.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):164-70 [17084556.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):359-68 [11466691.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):24-30 [19047283.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Chin Med J (Engl). 2007 Jun 20;120(12):1047-50 [17637220.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):508-17 [16491338.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1610-6 [16518798.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1114-22 [17206483.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):637-42 [8299085.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):514-9 [12243830.001]
  • [Cites] Ann Surg Oncol. 1997 Jul-Aug;4(5):421-4 [9259970.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):469-75 [11872294.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Eur J Surg Oncol. 2001 Sep;27(6):564-8 [11520090.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):346-54 [11986186.001]
  • [Cites] Eur J Surg Oncol. 2001 Aug;27(5):491-7 [11504522.001]
  • (PMID = 20162280.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


62. Leidinger B, Heyse T, Schuck A, Buerger H, Mommsen P, Bruening T, Fuchs S, Gosheger G: High incidence of metastatic disease in primary high grade and large extremity soft tissue sarcomas treated without chemotherapy. BMC Cancer; 2006;6:160
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High incidence of metastatic disease in primary high grade and large extremity soft tissue sarcomas treated without chemotherapy.
  • BACKGROUND: The risk of metastasis and the survival in patients with primary extremity soft tissue sarcomas is worse when tumour size is large and the grade of malignancy is high.
  • METHODS: We retrospectively reviewed the clinical outcome of 233 patients with a primary extremity soft tissue sarcoma treated between 1990 - 2000 with a mean follow-up of 35.8 (4-120) months in our institute.
  • 41 patients had high grade, deep and large tumours (>8 cm), an AJCC stage III (no evidence of metastasis prior to treatment) and were treated with limb salvage surgery and irradiation but stayed without additional chemotherapy.
  • [MeSH-major] Sarcoma / pathology. Sarcoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Orthop Scand Suppl. 2001 Feb;72(300):1-31 [11381580.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Clin Orthop Relat Res. 2002 Apr;(397):177-89 [11953609.001]
  • [Cites] Eur J Surg Oncol. 2002 Jun;28(4):431-6 [12099655.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4472-7 [12431971.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27 [12829150.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(13):1872-80 [12932665.001]
  • [Cites] Acta Oncol. 2003;42(5-6):516-31 [14596510.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):522-6 [15380587.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2659-67 [3995476.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):172-7 [3940616.001]
  • [Cites] Cancer. 1986 Feb 1;57(3):484-91 [3942981.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):480-8 [3819810.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1500-4 [3040219.001]
  • [Cites] J Bone Joint Surg Am. 1987 Sep;69(7):1074-8 [3654700.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Apr;14(4):693-9 [3350724.001]
  • [Cites] J Clin Oncol. 1988 May;6(5):854-62 [3367188.001]
  • [Cites] Can J Surg. 1989 Jan;32(1):69-73 [2910383.001]
  • [Cites] Acta Orthop Scand. 1989 Dec;60(6):687-92 [2696323.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):899-906 [2211257.001]
  • [Cites] Ann Surg. 1991 Sep;214(3):328-36; discussion 336-8 [1929613.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1485-92 [1938557.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1595-9 [1938569.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1992 Jan;4(1):36-43 [1736977.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(3):653-60 [1612967.001]
  • [Cites] Surg Gynecol Obstet. 1993 Feb;176(2):124-34 [8421799.001]
  • [Cites] J Surg Oncol. 1993 Apr;52(4):223-30 [8468983.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1652-9 [8156492.001]
  • [Cites] Eur J Cancer. 1994;30A(6):746-51 [7917531.001]
  • [Cites] J Surg Oncol. 1994 Oct;57(2):111-4 [7934061.001]
  • [Cites] Semin Surg Oncol. 1994 Sep-Oct;10(5):347-56 [7997728.001]
  • [Cites] Acta Orthop Scand. 1994 Oct;65(5):553-8 [7801762.001]
  • [Cites] Cancer. 1995 May 1;75(9):2299-306 [7712441.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 15;32(4):977-85 [7607972.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):869-77 [8622035.001]
  • [Cites] J Surg Oncol. 1996 Feb;61(2):90-9 [8606553.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):197-203 [9440743.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1599-608 [11527684.001]
  • (PMID = 16780601.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1550254
  •  go-up   go-down


63. Naka N, Joyama S, Tsukamoto Y, Yoshioka K, Hashimoto N, Ujiiye T, Hayashi T, Kawase M, Mano M, Ishiguro S, Myoui A, Ueda T, Yoshikawa H, Araki N, Itoh K: Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification. J Mol Diagn; 2005 May;7(2):187-97
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of SSX mRNA expression in human bone and soft tissue tumors using nucleic acid sequence-based amplification.
  • We have developed a competitive nucleic acid sequence-based amplification (NASBA) assay to analyze SSX mRNA expression in 211 bone and soft tissue tumors.
  • Further, SSX mRNA expression in stage III tumors was significantly higher than that in stage I or II tumors (P < 0.005).
  • [MeSH-major] Bone Neoplasms / genetics. Neoplasm Proteins / genetics. RNA, Messenger / analysis. Repressor Proteins / genetics. Self-Sustained Sequence Replication. Soft Tissue Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. COS Cells. Child. Female. Gene Expression. Humans. Male. Middle Aged. RNA, Neoplasm / analysis. RNA, Neoplasm / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6223-9 [10626816.001]
  • [Cites] Nucleic Acids Res. 1998 May 1;26(9):2250-1 [9547289.001]
  • [Cites] Lett Appl Microbiol. 2000 Jan;30(1):75-9 [10728566.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1654-62 [10749136.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4499-506 [10969798.001]
  • [Cites] Clin Cancer Res. 2000 Oct;6(10):3916-22 [11051238.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Oct 24;97(22):12198-203 [11027314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):629-34 [11149944.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3282-7 [11248070.001]
  • [Cites] J Surg Res. 2001 Jun 15;98(2):76-80 [11397121.001]
  • [Cites] J Immunol. 2002 Feb 15;168(4):1717-22 [11823502.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):640-2 [11920629.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 5;292(3):715-26 [11922625.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):448-53 [12216073.001]
  • [Cites] Immunol Rev. 2002 Oct;188:22-32 [12445278.001]
  • [Cites] Int J Biol Markers. 2002 Oct-Dec;17(4):219-23 [12521124.001]
  • [Cites] Cancer Immun. 2003 Oct 9;3:13 [14533943.001]
  • [Cites] Clin Chim Acta. 2004 Apr;342(1-2):115-26 [15026272.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Clin Orthop Relat Res. 1980 Nov-Dec;(153):106-20 [7449206.001]
  • [Cites] Nature. 1991 Mar 7;350(6313):91-2 [1706072.001]
  • [Cites] Science. 1991 Dec 13;254(5038):1643-7 [1840703.001]
  • [Cites] Nat Genet. 1994 Aug;7(4):502-8 [7951320.001]
  • [Cites] Immunity. 1995 Feb;2(2):167-75 [7895173.001]
  • [Cites] Melanoma Res. 1997 Aug;7 Suppl 2:S83-8 [9578421.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6919-23 [9618514.001]
  • [Cites] Int J Cancer. 1998 Jul 3;77(1):19-23 [9639388.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5211-6 [9560255.001]
  • [Cites] J Bone Joint Surg Am. 1998 Aug;80(8):1204-18 [9730132.001]
  • [Cites] Oncogene. 1998 Oct 15;17(15):2013-8 [9788446.001]
  • [Cites] Int J Cancer. 1999 Jan 18;80(2):219-30 [9935203.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):664-9 [10521804.001]
  • [Cites] EMBO J. 1995 May 15;14(10):2333-40 [7539744.001]
  • [Cites] J Exp Med. 1995 Sep 1;182(3):689-98 [7544395.001]
  • [Cites] Hum Mol Genet. 1995 Jun;4(6):1097-9 [7655467.001]
  • [Cites] Int J Cancer. 1995 Nov 3;63(3):375-80 [7591235.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4766-72 [8840996.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):965-71 [9378559.001]
  • [Cites] J Exp Med. 1998 Jan 19;187(2):265-70 [9432985.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):726-32 [10699956.001]
  • (PMID = 15858142.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Repressor Proteins; 164289-47-8 / synovial sarcoma X breakpoint proteins
  • [Other-IDs] NLM/ PMC1867521
  •  go-up   go-down


64. Chu QS, Forouzesh B, Syed S, Mita M, Schwartz G, Cooper J, Curtright J, Rowinsky EK: A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs; 2007 Aug;25(4):359-67
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas.
  • This phase II study evaluated the antitumor activity of the tetracycline analog COL-3, a potent inhibitor of metalloproteinases (MMPs), particularly MMP-2 and MMP-9, on a continuous oral schedule at a dose of 50 mg/m2 daily in patients with advanced and/or metastatic soft tissue sarcoma (STS).
  • A Simon two-stage design with multinomial stopping rule was employed, with 15 patients enrolled during the first stage of the study.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Sarcoma / drug therapy. Tetracyclines / pharmacology. Tetracyclines / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Endpoint Determination. Female. Humans. Male. Matrix Metalloproteinase Inhibitors. Middle Aged. Neoplasm Recurrence, Local. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Invest New Drugs. 2007 Aug;25(4):357. Copper, Joshua [corrected to Cooper, Joshua]
  • [Cites] J Pathol. 1998 Jul;185(3):256-61 [9771478.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4031-3 [10361099.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1389-94 [16549833.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1272-5 [11245418.001]
  • [Cites] Semin Perinatol. 1991 Apr;15(2):118-26 [1652159.001]
  • [Cites] Clin Cancer Res. 2004 Mar 15;10(6):1971-5 [15041714.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4434-9 [12431965.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:678-82 [10415806.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98(2):297-309 [11857423.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4882-8 [9354453.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):584-92 [11208854.001]
  • [Cites] Int J Pancreatol. 1997 Feb;21(1):1-12 [9127168.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):842-9 [15681529.001]
  • [Cites] Int J Cancer. 1993 Jun 19;54(4):614-8 [8514452.001]
  • [Cites] J Biopharm Stat. 1999 May;9(2):351-63 [10379698.001]
  • [Cites] Arch Dermatol. 2001 Apr;137(4):471-4 [11295928.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):441-51 [14585225.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):153-9 [11773164.001]
  • [Cites] Int J Cancer. 1991 Nov 11;49(5):666-72 [1657796.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):178-93 [11158186.001]
  • [Cites] J Cell Biol. 1992 Sep;118(5):1271-82 [1512297.001]
  • [Cites] Drugs. 2005;65(2):167-78 [15631540.001]
  • [Cites] J Am Board Fam Pract. 2002 May-Jun;15(3):239-41 [12038732.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2831-9 [15837997.001]
  • [Cites] Eur J Cancer. 2002 Mar;38(4):543-9 [11872347.001]
  • [Cites] Curr Med Chem. 2001 Feb;8(3):261-70 [11172681.001]
  • [Cites] Exp Cell Res. 2002 Apr 15;275(1):110-21 [11925109.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):420-3 [10950368.001]
  • [Cites] Pathobiology. 1998;66(1):5-16 [9577961.001]
  • [Cites] Am J Pathol. 1996 Jul;149(1):273-82 [8686751.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(3):CD003293 [12917960.001]
  • [Cites] J Clin Oncol. 2004 Dec 1;22(23):4683-90 [15570070.001]
  • [Cites] J Clin Pharmacol. 2003 Oct;43(10):1124-35 [14517195.001]
  • [Cites] Nat Med. 1996 Apr;2(4):461-2 [8597958.001]
  • [Cites] Semin Cancer Biol. 1990 Apr;1(2):99-106 [2103492.001]
  • [Cites] Adv Dent Res. 1998 Nov;12(2):114-8 [9972133.001]
  • [Cites] Int J Cancer. 1997 Aug 7;72(4):556-64 [9259391.001]
  • [Cites] Histol Histopathol. 2003 Oct;18(4):1035-40 [12973672.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3296-302 [12947065.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1260-70 [9293916.001]
  • [Cites] Adv Dent Res. 1998 Nov;12(2):12-26 [9972117.001]
  • [Cites] J Rheumatol. 1998 Sep;25(9):1807-12 [9733464.001]
  • [Cites] Br J Cancer. 1999 May;80(5-6):733-43 [10360651.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):785-91 [11157032.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1B):639-45 [12680160.001]
  • [Cites] J Immunol. 1999 Sep 15;163(6):3459-67 [10477618.001]
  • [Cites] APMIS. 1999 Jan;107(1):120-7 [10190288.001]
  • [Cites] Pharm Res. 2002 Nov;19(11):1655-62 [12458671.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6512-21 [15475438.001]
  • (PMID = 17237909.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Matrix Metalloproteinase Inhibitors; 0 / Tetracyclines; 0 / tetracycline CMT-3
  •  go-up   go-down


65. Demiralp B, Ozdemir MT, Erler K, Basbozkurt M: Type 1 neurofibromatosis and adult extremity sarcoma. A report of two cases. Acta Orthop Belg; 2007 Jun;73(3):403-7
Genetic Alliance. consumer health - Neurofibromatosis type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type 1 neurofibromatosis and adult extremity sarcoma. A report of two cases.
  • We report two cases of malignant soft-tissue tumours--one myxoid malignant fibrous histiocytoma and one pleomorphic rhabdomyosarcoma--which were diagnosed in two young adult patients with type 1 neurofibromatosis (NF 1).
  • The tumours were stage II and III respectively.
  • Diagnoses of myxoid malignant fibrous histiocytoma and pleomorphic rhabdomyosarcoma in adult NF 1 patients are exceedingly rare.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / complications. Neoplasms, Multiple Primary. Neurofibromatosis 1 / complications. Rhabdomyosarcoma / complications. Soft Tissue Neoplasms
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17715736.001).
  • [ISSN] 0001-6462
  • [Journal-full-title] Acta orthopaedica Belgica
  • [ISO-abbreviation] Acta Orthop Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


66. Mastrangelo G, Fadda E, Cegolon L, Montesco MC, Ray-Coquard I, Buja A, Fedeli U, Frasson A, Spolaore P, Rossi CR: A European project on incidence, treatment, and outcome of sarcoma. BMC Public Health; 2010;10:188
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A European project on incidence, treatment, and outcome of sarcoma.
  • BACKGROUND: Sarcomas are rare tumors (1-2% of all cancers) of mesenchymal origin that may develop in soft tissues and viscera.
  • Since the International Classification of Disease (ICD) attributes visceral sarcomas (VS) to the organ of origin, the incidence of sarcoma is grossly underestimated.
  • In view of the above the European Commission funded the project called Connective Tissues Cancers Network (CONTICANET), to improve the prognosis of sarcoma patients by increasing the level of standardization of diagnostic and therapeutic procedures through a multicentre collaboration.
  • The first investigation aims to build the population-based incidence of sarcoma in a two-year period, using the new 2002 WHO classification and the "second opinion" given by an expert regional pathologist on the initial diagnosis by a local pathologist.
  • Pathology reports and clinical records will be the sources of information.The second study aims to compare the effects on survival or relapse-free period - allowing for histological subtypes, clinical stage, primary site, age and gender - when the disease was treated or not according to the clinical practice guidelines (CPGs).
  • The first protocol was accepted by the other researchers, therefore the incidence of sarcoma will be assessed in three European regions, Rhone-Alpes and Aquitaine (France) and Veneto (Italy), where the geographic distribution of sarcoma will be compared after taking into account age and gender.
  • [MeSH-major] Research Design. Sarcoma / diagnosis. Sarcoma / epidemiology. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Community Networks. Diagnostic Techniques and Procedures / standards. Epidemiologic Methods. Europe / epidemiology. Female. Humans. Incidence. Male. Multivariate Analysis. Pilot Projects. Population Surveillance / methods. Sex Distribution. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Dec 1;86(11):2426-35 [10590387.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2922-30 [17013893.001]
  • [Cites] Eur J Surg Oncol. 2000 Sep;26(6):548-51 [11184316.001]
  • [Cites] Am J Clin Pathol. 2001 Oct;116(4):473-6 [11601130.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):307-15 [14760127.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):543-8 [14962721.001]
  • [Cites] Am J Epidemiol. 1984 Oct;120(4):626-34 [6383024.001]
  • [Cites] JAMA. 1988 Sep 23-30;260(12):1743-8 [3045356.001]
  • [Cites] Br J Cancer. 1991 Aug;64(2):315-20 [1892759.001]
  • [Cites] Acta Orthop Scand. 1994 Feb;65(1):47-50 [8154283.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1136-9 [7953340.001]
  • [Cites] JAMA. 1997 Nov 19;278(19):1591-5 [9370505.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1692-6 [9448617.001]
  • [Cites] Eur J Cancer Prev. 1997 Oct;6(5):442-66 [9466116.001]
  • [Cites] BMJ. 1998 Jul 11;317(7151):93-4 [9657781.001]
  • [Cites] Semin Radiat Oncol. 1999 Oct;9(4):328-48 [10516380.001]
  • [Cites] Histopathology. 2006 Jan;48(1):3-12 [16359532.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):280-4 [10680896.001]
  • (PMID = 20384990.001).
  • [ISSN] 1471-2458
  • [Journal-full-title] BMC public health
  • [ISO-abbreviation] BMC Public Health
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2882909
  •  go-up   go-down


67. Guo W, Ji T, Yant Y: [Endoprosthetic reconstruction after wide resection of sarcoma in lower extremities]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Oct;20(10):970-4
MedlinePlus Health Information. consumer health - Bone Grafts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoprosthetic reconstruction after wide resection of sarcoma in lower extremities].
  • OBJECTIVE: To assess the clinical outcome of the limb salvage surgery and complications occurring in the lower extremities after a wide resection of sarcoma.
  • According to the Enneking staging, 3 patients were grouped in the stage of II A, 85 in I B, and 12 in III.
  • Of the 7 patients, 4 had a recurrence of the soft tissue tumor for which resection was performed; the other 3 patients underwent amputation of the diseased limb.
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Humans. Lower Extremity. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140065.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


68. Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, Collini P, Radaelli S, Fiore M, Gronchi A: Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol; 2007 Dec;14(12):3542-51
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution.
  • BACKGROUND: Epithelioid sarcoma (ES) is a rare subtype of soft-tissue sarcoma of unknown histogenesis.
  • In univariable analysis, nodular ES was associated with smaller tumor size, distal limb locations, earlier classification of malignant tumor (TNM) stage, and higher amputation rate.
  • Better prognosis is associated with single localized disease stage and no occurrence of locoregional spread.
  • [MeSH-major] Epithelioid Cells / pathology. Sarcoma / mortality. Soft Tissue Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909905.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. El-Sherbiny M: Pedicled gastrocnemius flap: clinical application in limb sparing surgical resection of sarcoma around the knee region and popliteal fossa. J Egypt Natl Canc Inst; 2008 Jun;20(2):196-207
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pedicled gastrocnemius flap: clinical application in limb sparing surgical resection of sarcoma around the knee region and popliteal fossa.
  • OBJECTIVE: To highlight on the versatility of superiorly based pedicled gastrocnemius muscle flap in the limb-sparing surgery for bone or soft tissue sarcoma around the knee and popliteal fossa.
  • PATIENTS AND METHODS: A total of 30 patients with localized bone or soft tissue sarcoma around the knee and popliteal fossa were treated with limb-salvage procedure.
  • The study included 5 cases with bone sarcoma of the distal femur, 15 cases having bone sarcoma of proximal tibia and 10 cases having soft tissue sarcoma around the knee region and popliteal fossa.
  • According to the Enneking staging system, 19 patients had stage IIB and 11 had stage IIA.
  • Patients having bone sarcoma of the proximal tibia were subjected to wide resection, endoprosthetic reconstruction and reconstruction of the extensor mechanism by the medial gastrocnemius muscle flap.
  • Patients having bone sarcoma of the distal femur were subjected to wide resection, endo prosthetic reconstruction and coverage of the prosthesis and rebalance of the patellar tendon by the medial gastrocnemius flap.
  • Patients having soft tissue sarcoma were subjected to wide resection and soft tissue coverage with either medial or lateral myocutaneous gastrocnemius flap or muscle flap with grafting.
  • Resection with a negative bony and soft tissue margins could be achieved in all cases.
  • A total of 30 flaps were used and included medial gastrocnemius muscle flaps in 21 cases (15 cases had proximal tibia endoprothesis, 5 cases had distal femur endoprothesis, 2 cases had soft tissue sarcoma infiltrating the chin of tibia), myocutaneous gastrocnemius flaps in 8 cases having soft tissue sarcoma (5 had medial head flap and 3 cases lateral head flap).
  • CONCLUSION: The unique vascularization of the gastrocnemius muscle (one pedicle to each head), the size of the muscle belly, the fact that it is situated in the dissection field and that its transfer does not affect the function of the spared limb too adversely, makes it particularly suitable for limb sparing procedures for sarcoma in the region of the knee and popliteal fossa.
  • The medial head is the workhorse muscle flap for soft tissue coverage of knee endoprothesis and reconstruction of extensor mechanism.
  • Reconstruction of the soft issue defect improves wound healing, protects exposed deep structures and subsequently prevents wound problems, delays adjuvant therapy and secondary amputation.
  • [MeSH-major] Bone Neoplasms / surgery. Knee / surgery. Muscle, Skeletal / surgery. Popliteal Artery / surgery. Reconstructive Surgical Procedures / methods. Sarcoma / surgery. Surgical Flaps
  • [MeSH-minor] Adolescent. Adult. Child. Female. Follow-Up Studies. Humans. Limb Salvage. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20029476.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


70. Raney B, Anderson J, Breneman J, Donaldson SS, Huh W, Maurer H, Michalski J, Qualman S, Ullrich F, Wharam M, Meyer W, Soft-Tissue Sarcoma Committee of the Children's Oncology Group, Arcadia, California, USA: Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group. Pediatr Blood Cancer; 2008 Jul;51(1):17-22
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV, 1978-1997: report from the Children's Oncology Group.
  • PURPOSE: Determine outcome of patients with cranial parameningeal sarcoma and concurrent metastases treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV.
  • PATIENTS: We identified 91 patients in the database, which includes newly diagnosed subjects <21 years old with rhabdomyosarcoma (RMS) and undifferentiated sarcoma, and reviewed their charts in detail.
  • CONCLUSIONS: Cure was possible for some patients with metastatic cranial parameningeal sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18266224.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-98543; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / CA-72989; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA-29511
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


71. Yabe H, Tsukahara T, Kawaguchi S, Wada T, Sato N, Morioka H, Yabe H: Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis. Oncol Rep; 2008 Jan;19(1):129-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis.
  • Ewing's sarcoma family of tumors (ESFT) is comprised of highly malignant bone and soft tissue tumors in children and young adults.
  • Of the 11 variables analyzed, stage III disease, inadequate surgical margins and PBF overexpression were significantly associated with decreased disease-free and overall survival.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. Bone Neoplasms / metabolism. Bone Neoplasms / pathology. Sarcoma, Ewing / metabolism. Sarcoma, Ewing / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Immunohistochemistry. Infant. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097586.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / osteosarcoma-associated antigen
  •  go-up   go-down


72. Cherix S, Speiser M, Matter M, Raffoul W, Liénard D, Theumann N, Mouhsine E, Mirimanoff RO, Leyvraz S, Lejeune FJ, Leyvraz PF: Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients. J Surg Oncol; 2008 Sep 1;98(3):148-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas: long-term results on efficacy and limb salvage in a selected group of patients.
  • BACKGROUND AND OBJECTIVES: Isolated limb perfusion with TNF-alpha and melphalan (TM-ILP) is a limb salvage therapy for non-resectable soft tissue sarcomas (STS) of the extremities.
  • METHODS: Between February 1992 and March 2006, 57 TM-ILPs were performed on 51 patients with 88% high grade and 84% advanced stage tumors.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Limb Salvage. Melphalan / administration & dosage. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / drug therapy. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18668638.001).
  • [ISSN] 1096-9098
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


73. Sultan I, Rodriguez-Galindo C, Saab R, Yasir S, Casanova M, Ferrari A: Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients. Cancer; 2009 Aug 1;115(15):3537-47
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology, and End Results program, 1983 to 2005: an analysis of 1268 patients.
  • BACKGROUND: Synovial sarcoma (SS) is a typical soft tissue sarcoma subtype crosswise between the pediatric and the adult age groups.
  • Less satisfactory overall outcome has been recorded in adult series.
  • RESULTS: No major differences in stage distribution (localized, regional, and distant stage) were observed comparing the 2 age groups.
  • In multivariate analysis, adult patients had significantly higher mortality rates than children after adjusting for other variables.
  • CONCLUSIONS: Children and adults with SS have a similar clinical presentation but a dissimilar outcome, suggesting that factors other than unfavorable clinical features might be involved in the unsatisfactory outcome of adult SS patients.
  • It remains to be ascertained whether this difference is related to biological variables or to historically different treatment approaches adopted in pediatric versus adult patients.
  • [MeSH-major] Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Infant. Male. Middle Aged. Prognosis. SEER Program. Treatment Outcome

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • (PMID = 19514087.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Adam Z, Veselý K, Krejcí M, Pour L, Fakan F, Soumarová R, Neubauer J, Vanícek J, Cerný J, Kren L, Bolcák K, Smardová L, Hájek R, Mayer J: [Interdigitating dendritic cell sarcoma of lower extremities resistant to high dose chemotherapy BEAM with peripheral blood stem cell transplantation]. Vnitr Lek; 2009 Feb;55(2):147-57
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interdigitating dendritic cell sarcoma of lower extremities resistant to high dose chemotherapy BEAM with peripheral blood stem cell transplantation].
  • Interdigitating dendritic cell sarcoma is a rare neoplasm forming part of the group of malignancies derived from histocytic cell line.
  • The pathological process affected proximal tibial epiphysis and adjacent soft tissues.
  • The first FDG-PET examination performed in the process of determining the clinical stage of the disease showed a high activity in the site of primary tumour (SUV 7.71) and in the site of regional inguinal node (SUV 4.25).
  • Histological examination of a diagnostic excision specimen of the tumour in the tibia and the extirpated enlarged regional nodes in the left groin led to the diagnosis of interdigitating dendritic cell sarcoma.
  • One month after ESHAP chemotherapy, BEAM high-dose chemotherapy with autologous transplantation of blood forming tissue was performed.
  • The activity corresponded to the presence of viable tumour tissue in the primary nidus and new metastases in inguinal nodes, without proofs of further proliferation at the time.
  • To our knowledge, the above description is the first documented case of interdigitating dendritic cell sarcoma located in the tibia and crus soft tissue.
  • We have not found any description of high-dose therapy supported by autologous transplantation of blood-forming tissue for this type of tumour in relevant literature.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Dendritic Cell Sarcoma, Interdigitating / therapy. Drug Resistance, Neoplasm. Leg. Peripheral Blood Stem Cell Transplantation. Soft Tissue Neoplasms / therapy. Tibia
  • [MeSH-minor] Adult. Carmustine / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Humans. Male. Melphalan / administration & dosage. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348397.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen
  • [Number-of-references] 69
  •  go-up   go-down


75. Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM: The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer; 2006 Jan 1;106(1):156-62
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma.
  • BACKGROUND: Both patients with soft tissue sarcoma (STS) and patients with melanoma have limited treatment possibilities once the tumor has metastasized systemically.
  • In this study, the authors investigated the palliative value of the ILP procedure to avoid amputation in patients who had Stage IV STS and melanoma.
  • METHODS: From 1991 to 2003, of 339 tumor necrosis factor alpha (TNF)-based ILPs, 51 procedures were performed for either Stage IV STS (n = 37 patients) or Stage IV melanoma (n = 14 patients).
  • RESULTS: The overall response in patients with Stage IV STS was 84%, and their median survival was 12 months after ILP.
  • In the patients with Stage IV melanoma, the complete response rate was 43%.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Melphalan / therapeutic use. Palliative Care. Sarcoma / drug therapy. Tumor Necrosis Factor-alpha / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation. Arm. Female. Humans. Leg. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Recombinant Proteins / administration & dosage. Recombinant Proteins / adverse effects. Recombinant Proteins / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 16323177.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Recombinant Proteins; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


76. Terazawa K, Otsuka H, Morita N, Yamashita K, Nishitani H: Clear-cell sarcoma of the small intestine detected by FDG-PET/CT during comprehensive examination of an inflammatory reaction. J Med Invest; 2009 Feb;56(1-2):70-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear-cell sarcoma of the small intestine detected by FDG-PET/CT during comprehensive examination of an inflammatory reaction.
  • Clear-cell sarcoma (CCS) is a rare, malignant, soft-tissue tumor, which involves the extremities, particularly the foot and foot joint tendons and aponeuroses.
  • We report a case of early-stage CCS of the small intestine detected by (18)F-fluoro-2-deoxy D-glucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT) during the comprehensive examination of an inflammatory reaction.
  • [MeSH-major] Intestinal Neoplasms / radiography. Intestinal Neoplasms / radionuclide imaging. Sarcoma, Clear Cell / radiography. Sarcoma, Clear Cell / radionuclide imaging
  • [MeSH-minor] Female. Fluorodeoxyglucose F18. Humans. Positron-Emission Tomography. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262017.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


77. Blazer DG 3rd, Lazar AJ, Xing Y, Askew RL, Feig BW, Pisters PW, Pollock RE, Lev D, Hunt KK, Cormier JN: Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry. Cancer; 2009 Jul 1;115(13):2971-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the Surveillance, Epidemiology, and End Results registry.
  • BACKGROUND: The authors compared disease-specific survival (DSS) in stage-specific subgroups of patients with clear cell sarcoma, including those with lymph node metastases (N1M0) and those with distant metastases (N0M1).
  • METHODS: Clinical data regarding soft tissue sarcoma patients were obtained from The University of Texas M. D.
  • When possible, clear cell sarcoma diagnoses were confirmed using fluorescence in situ hybridization or reverse-transcription polymerase chain reaction.
  • RESULTS: Fifty-two patients at MDACC and 130 SEER patients were diagnosed with clear cell sarcoma.
  • After adjustment, the hazards ratio (HR) for dying was 2.79 for N1M0 disease (95% confidence interval [95% CI], 1.32-5.91) and 11.37 (95% CI, 5.19-24.91) for N0M1 disease compared with stage II disease (P < .001).
  • CONCLUSIONS: The findings of the current study suggest that patients with N1M0 clear cell sarcoma have 5-year DSS that is more similar to that of patients with stage III than stage IV soft tissue sarcoma.
  • [MeSH-major] Sarcoma / genetics. Sarcoma / pathology. Sarcoma, Clear Cell / genetics. Sarcoma, Clear Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. SEER Program. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19402173.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Nowecki ZI, Rutkowski P, Kulik J, Siedlecki JA, Ruka W: Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level. Br J Dermatol; 2008 Sep;159(3):597-605
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
  • OBJECTIVES: This study assessed the prognostic value of multimarker reverse transcriptase-polymerase chain reaction (RT-PCR) assay in lymphatic drainage (LY) after lymph node dissection (LND) and of preoperative serum lactate dehydrogenase (LDH) levels in American Joint Committee on Cancer (AJCC) stage III melanoma patients.
  • METHODS: We collected 24-h LY from 255 stage III melanoma patients after radical LND [114, completion LND after positive sentinel node biopsy (CLND); 141, therapeutic LND for clinically/cytologically detected regional nodal metastases (TLND)].
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / genetics. Biomarkers / blood. Disease-Free Survival. Female. Follow-Up Studies. Humans. L-Lactate Dehydrogenase / blood. Lymph Node Excision. Lymphatic Metastasis. MART-1 Antigen. Male. Middle Aged. Monophenol Monooxygenase / genetics. Multivariate Analysis. Neoplasm Proteins / genetics. Neoplasm Staging. Predictive Value of Tests. Proportional Hazards Models. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18616789.001).
  • [ISSN] 1365-2133
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / MART-1 Antigen; 0 / MLANA protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


79. Admiraal R, van der Paardt M, Kobes J, Kremer LC, Bisogno G, Merks JH: High-dose chemotherapy for children and young adults with stage IV rhabdomyosarcoma. Cochrane Database Syst Rev; 2010;(12):CD006669
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy for children and young adults with stage IV rhabdomyosarcoma.
  • BACKGROUND: Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Rhabdomyosarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Child. Controlled Clinical Trials as Topic. Disease-Free Survival. Humans. Neoplasm Staging. Stem Cell Transplantation / methods. Transplantation, Autologous. Young Adult

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21154373.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


80. Zivanovic O, Leitao MM, Iasonos A, Jacks LM, Zhou Q, Abu-Rustum NR, Soslow RA, Juretzka MM, Chi DS, Barakat RR, Brennan MF, Hensley ML: Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. J Clin Oncol; 2009 Apr 20;27(12):2066-72
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems.
  • We aimed to determine whether the American Joint Committee on Cancer (AJCC) soft tissue sarcoma (STS) staging system is more accurate in predicting progression-free survival (PFS) and overall survival (OS).
  • Stage-specific PFS and OS rates for stages I, II, and III differed substantially between the two staging systems.
  • Thus, despite the marked stage-specific differences in 5-year PFS and OS rates for stages I, II, and III, both systems had similar concordance indices.
  • CONCLUSION: Estimates of stage-specific PFS and OS for uterine LMS were altered substantially when using the AJCC versus FIGO staging system.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. International Agencies. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 2008 Apr;198(4):457.e1-5; discussion 457.e5-6 [18395039.001]
  • [Cites] Am J Obstet Gynecol. 1979 Jul 1;134(5):557-64 [453295.001]
  • [Cites] Int J Oncol. 2008 May;32(5):1111-7 [18425339.001]
  • [Cites] N Engl J Med. 1985 Jun 20;312(25):1604-8 [4000199.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] J Natl Cancer Inst. 1986 Mar;76(3):399-402 [3456457.001]
  • [Cites] Am J Obstet Gynecol. 1987 Mar;156(3):660-2 [3826216.001]
  • [Cites] Obstet Gynecol. 1988 Jun;71(6 Pt 1):845-50 [2453004.001]
  • [Cites] World J Surg. 1988 Jun;12(3):326-31 [3400243.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):35-9 [2354406.001]
  • [Cites] Ann Intern Med. 1991 Dec 1;115(11):906-7 [1952481.001]
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] Gynecol Oncol. 1993 Jul;50(1):105-9 [8349151.001]
  • [Cites] Am J Surg Pathol. 1994 Jun;18(6):535-58 [8179071.001]
  • [Cites] Obstet Gynecol. 1994 Jun;83(6):1015-20 [8190416.001]
  • [Cites] Acta Oncol. 1995;34(6):797-802 [7576748.001]
  • [Cites] Stat Med. 1996 Feb 28;15(4):361-87 [8668867.001]
  • [Cites] Gynecol Oncol. 1996 Jul;62(1):25-32 [8690287.001]
  • [Cites] Gynecol Oncol. 1999 Aug;74(2):196-201 [10419731.001]
  • [Cites] Stat Med. 1999 Sep 15-30;18(17-18):2529-45 [10474158.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):163-71 [16331596.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3819-20 [16864852.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3967-72 [16864855.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1316-22 [17416852.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4679-85 [17299097.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3576-81 [17704404.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):820-30 [18189292.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1425-31 [10717626.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):791-6 [11821462.001]
  • [Cites] J Clin Oncol. 2002 Jun 15;20(12):2824-31 [12065559.001]
  • [Cites] Curr Opin Urol. 2003 Mar;13(2):111-6 [12584470.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):460-9 [12798712.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):209-12 [14529683.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):648-52 [14766261.001]
  • [Cites] Stat Med. 2004 Mar 15;23(5):723-48 [14981672.001]
  • [Cites] J Clin Oncol. 2004 Sep 15;22(18):3668-76 [15302909.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):808-18 [18378136.001]
  • (PMID = 19255317.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3646302
  •  go-up   go-down


81. Gürkan V, Ozger H: [Sarcomas of the hand]. Acta Orthop Traumatol Turc; 2007 Aug-Oct;41(4):286-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated patients who underwent surgical treatment for sarcoma of the hand.
  • METHODS: Between 1990 and 2006, eight patients (5 males, 3 females; mean age 39.6 years; range 26 to 67 years) with hand sarcoma received treatment at two centers.
  • The lesions arose from soft tissue in five cases, and from bone in three cases.
  • RESULTS: Mortality occurred in two patients due to multiple metastases, who had synovial sarcoma in the carpal region and clear cell sarcoma in the wrist, respectively.
  • Both patients had stage III disease on presentation.
  • Of three patients with tumors localized in the fingers, two had stage IA, and one had stage IB disease.
  • Apart from clear cell sarcoma, diagnoses of other wrist tumors were stage IIB epithelioid sarcoma and malignant fibrous histiocytoma.
  • [MeSH-major] Hand. Sarcoma / surgery. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Severity of Illness Index. Treatment Outcome. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18180558.001).
  • [ISSN] 1017-995X
  • [Journal-full-title] Acta orthopaedica et traumatologica turcica
  • [ISO-abbreviation] Acta Orthop Traumatol Turc
  • [Language] tur
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


82. Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, Wright JJ, Schwartz GK: A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer; 2005 Apr 1;103(7):1431-8
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Two arms were opened, each using a Simon two-stage design.
  • Arm A included patients with osteogenic sarcoma, Ewing sarcoma, and rhabdomyosarcoma.
  • Arm B accrued patients with other types of soft tissue sarcomas.
  • Due to the inactivity of this agent, the study was closed after the first stage of accrual.
  • CONCLUSIONS: Bortezomib has minimal activity in soft tissue sarcoma as a single agent.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / drug therapy. Boronic Acids / therapeutic use. Proteasome Inhibitors. Pyrazines / therapeutic use. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bortezomib. Drug Administration Schedule. Fatigue / chemically induced. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nervous System Diseases / chemically induced. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15739208.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01-CM17105; United States / NCI NIH HHS / CA / P01-CA47179
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


83. Takase K, Suzuki H, Matsuoka H: The usefulness of latissimus dorsi transfer for reconstruction for malignant fibrous histiocytoma in the infraspinatus muscle region: a case report. West Indian Med J; 2010 Jan;59(1):106-9
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant fibrous histiocytoma (MFH) is a type of highly malignant soft tissue sarcoma with a predilection for the extremities of adults.
  • We report a patient with MFH in the infraspinatus muscle for which wide resection including total resection of the infraspinatus muscle was performed, followed by transfer of the latissimus dorsi muscle for shoulder reconstruction in a one-stage operation with good postoperative function.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / surgery. Muscle, Skeletal / pathology. Muscle, Skeletal / surgery. Reconstructive Surgical Procedures / methods. Shoulder / surgery. Soft Tissue Neoplasms / surgery. Surgical Flaps
  • [MeSH-minor] Adult. Biopsy. Contrast Media. Female. Gadolinium DTPA. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931927.001).
  • [ISSN] 0043-3144
  • [Journal-full-title] The West Indian medical journal
  • [ISO-abbreviation] West Indian Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Jamaica
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


84. Eyesan SU, Obalum DC, Onovo DO, Ketiku KK, Abdulkareem FB: Clinico-pathologic patterns of extremity liposarcoma. Niger Postgrad Med J; 2010 Mar;17(1):27-9
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Demographic and clinical data ( including age, gender, presenting complaints anatomic location of lesions ), histologic type, clinical stage and treatment outcome were collected using a prepared proforma and analysed.
  • RESULTS: Liposarcoma accounted for 6 [27.3%] of 22 cases of soft tissue sarcomas seen within the study period.
  • All presented at stage T2bNoMo.
  • CONCLUSION: Liposarcoma is the commonest extremity soft tissue sarcoma seen in our centre, the myxoid type being the commonest histologic subtype.
  • [MeSH-major] Liposarcoma / pathology. Liposarcoma / surgery. Soft Tissue Neoplasms / pathology. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Extremities. Follow-Up Studies. Hospitals, Special. Humans. Male. Middle Aged. Neoplasm Staging. Nigeria. Orthopedics. Prospective Studies. Radiotherapy, Adjuvant. Survival Rate. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348979.001).
  • [ISSN] 1117-1936
  • [Journal-full-title] The Nigerian postgraduate medical journal
  • [ISO-abbreviation] Niger Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


85. Turcotte RE, Ferrone M, Isler MH, Wong C: Outcomes in patients with popliteal sarcomas. Can J Surg; 2009 Feb;52(1):51-5
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Soft-tissue sarcoma involving the popliteal fossa remains challenging because it is difficult to achieve wide margins with limb salvage in this location.
  • Frequent histologic diagnoses were liposarcoma (n = 6), synovial sarcoma (n = 4) and leiomyosarcoma (n = 3).
  • American Joint Committee on Cancer staging was as follows: 4 patients had stage IIa disease, 3 patients had stage IIb, 10 patients had stage III and 1 patient had stage IV disease.
  • [MeSH-major] Knee. Outcome Assessment (Health Care). Sarcoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Amputation / statistics & numerical data. Chemotherapy, Adjuvant. Databases, Factual. Female. Humans. Limb Salvage. Lung Neoplasms / secondary. Male. Middle Aged. Prospective Studies. Radiotherapy, Adjuvant. Retrospective Studies. Sciatic Nerve / surgery. Surgical Wound Dehiscence / etiology. Surgical Wound Infection / etiology. Thrombophlebitis / etiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 2000 Apr;73(4):206-11 [10797333.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):512-7 [17174515.001]
  • [Cites] Acta Orthop Scand. 2001 Apr;72(2):160-6 [11372947.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):476-82 [15078635.001]
  • [Cites] Ann Surg. 1968 Jul;168(1):47-53 [4299767.001]
  • [Cites] J Bone Joint Surg Am. 1980 Sep;62(6):1027-30 [7000786.001]
  • [Cites] Cancer. 1981 Mar 1;47(5):1005-22 [7226034.001]
  • [Cites] Cancer. 1986 Apr 15;57(8):1632-9 [3948134.001]
  • [Cites] Clin Orthop Relat Res. 1986 Mar;(204):9-24 [3456859.001]
  • [Cites] Acta Orthop Scand. 1987 Oct;58(5):516-22 [3425281.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):817-23 [3338039.001]
  • [Cites] Cancer. 1989 Apr 1;63(7):1437-51 [2646010.001]
  • [Cites] J Bone Joint Surg Am. 1989 Mar;71(3):370-5 [2925710.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):899-906 [2211257.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1493-9 [1938558.001]
  • [Cites] J Surg Oncol. 1993 Apr;52(4):223-30 [8468983.001]
  • [Cites] Clin Orthop Relat Res. 1993 Apr;(289):19-31 [8472413.001]
  • [Cites] Clin Orthop Relat Res. 1993 Apr;(289):73-80 [8472434.001]
  • [Cites] Eur J Cancer. 1994;30A(6):746-51 [7917531.001]
  • [Cites] Cancer. 1995 Oct 15;76(8):1398-405 [8620414.001]
  • [Cites] Curr Probl Surg. 1996 Oct;33(10):817-72 [8885853.001]
  • [Cites] Qual Life Res. 1996 Oct;5(5):508-16 [8973131.001]
  • [Cites] Clin Orthop Relat Res. 1999 Jan;(358):90-100 [9973980.001]
  • [Cites] Radiother Oncol. 2005 Apr;75(1):48-53 [15948265.001]
  • [Cites] Clin Orthop Relat Res. 2007 Feb;455:225-33 [16957647.001]
  • [Cites] Surg Oncol. 1999 Dec;8(4):211-4 [11128835.001]
  • (PMID = 19234652.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2637647
  •  go-up   go-down


86. Wakulińska A, Dembowska-Bagińska B, Cienciała M, Bothur-Nowacka J, Kościesza A, Pakuła-Kościesza I, Perek D: [Results of the treatment of paediatric non-rhabdomyosarcoma. One centre experience]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):819-29
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-rhabdomyosarcoma soft tissue sarcomas (NR STS) are a rare group of neoplasms of mesenchymal origin.
  • Results of treatment were analyzed in relation to stage, tumour diameter, extent of surgery and response to chemotherapy.
  • Early stage, tumour size less than 5 cm in diameter, radical surgery, complete and very good response to induction chemotherapy had a significant influence on survival.
  • CONCLUSIONS: Our results indicate that besides stage and tumour size, radical surgery played key role in the treatment of NRMSSTS and that radical resections were possible to perform after induction chemotherapy in 33% of patients with primarily unresectable tumours.
  • High number of patients with stage IV disease at diagnosis, occurrence of distant relapses and good response to chemotherapy indicate the necessity for the use of chemotherapy in patients with NR STS.
  • [MeSH-major] Sarcoma / epidemiology. Sarcoma / therapy. Soft Tissue Neoplasms / epidemiology. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Male. Poland / epidemiology. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317913.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


87. Xu J, Sun H, Xiao Y: [Application of medial head gastrocnemius muscle flap to limb-salvage operation of proximal tibial malignant tumor]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2007 Apr;21(4):352-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among them, there were 4 patients with osteosarcoma, 6 with malignant fibrous histocytoma, 1 with malignant giant cell tumor, 1 with synovial sarcoma, and 1 with Ewing's sarcoma.
  • According to the Enneking staging system, 1 case was in Stage I B, 9 in Stage II A, and 3 in Stage II B.
  • All of the patients underwent the medial head of the gastrocnemius muscle flap transposition to reconstruct the soft tissues after resection of the tumors and reconstruction of the bone defect by prothesis or bone-graft or the two methods combined.
  • The patient with Ewing's sarcoma had a local tumor recurrence 18 months after operation; though treated with the focal cleaning and the bone cement filling, the patient still developed lung metastasis of the tumor 26 months after operation.
  • CONCLUSION: The flap transposition of the medial head of the gastrocnemius muscle can reconstruct the soft tissue defect, decrease the local complication rate and improve the clinical outcome of the limb salvage for the proximal tibia malignant tumor.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage / methods. Osteosarcoma / surgery. Soft Tissue Injuries / surgery. Surgical Flaps / blood supply. Tibia
  • [MeSH-minor] Adolescent. Adult. Arthroplasty, Replacement, Knee. Bone Transplantation / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17546876.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


88. J BH, M S, T D, R C, W BB, M O, H B, T B, M M, F K, A G, M H, T D, K R: [Retroperitoneal sarcomas: a single center experience]. Cancer Radiother; 2008 Sep;12(5):331-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To analyse the management and clinical outcome of patients treated for retroperitonal soft tissue sarcoma and to identify prognosis factors.
  • Among the following factors, sex, age, symptom duration, tumor size, histologic type, histologic grade, resection type, mitotic index, necrosis extension, histologic differentiation, and AJCC stage, only mitotic index factor (scale 1,2 versus scale 3) significantly influenced patient survival (p = 0.02).
  • CONCLUSIONS: This study re-emphasizes the poor outcome of patients with retroperitoneal sarcoma.
  • [MeSH-major] Retroperitoneal Neoplasms. Sarcoma
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18434228.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


89. Hardes J, Gebert C, Schwappach A, Ahrens H, Streitburger A, Winkelmann W, Gosheger G: Characteristics and outcome of infections associated with tumor endoprostheses. Arch Orthop Trauma Surg; 2006 Jul;126(5):289-96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two-stage reimplantation of an endoprosthesis was successful in 14 patients but subsequently failed in one patient.
  • A poor soft tissue condition was a significant (P<0.05) risk factor for failed limb salvage.
  • No patient receiving chemotherapy with a poor soft tissue condition had limb salvage surgery.
  • Limb salvage failed mostly in the case of a poor soft tissue condition.
  • In these cases repeated revision surgery should be avoided and ablative surgery recommended at an early stage.
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / drug therapy. Bone Neoplasms / surgery. Child. Female. Femur / surgery. Humans. Humerus / surgery. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasms, Bone Tissue / drug therapy. Neoplasms, Bone Tissue / surgery. Reoperation. Retrospective Studies. Sarcoma / drug therapy. Sarcoma / surgery. Tibia / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16628430.001).
  • [ISSN] 0936-8051
  • [Journal-full-title] Archives of orthopaedic and trauma surgery
  • [ISO-abbreviation] Arch Orthop Trauma Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


90. Rutkowski P, Nowecki ZI, Zdzienicki M, Michej W, Symonides M, Rosinska M, Dziewirski W, Bylina E, Ruka W: Cutaneous melanoma with nodal metastases in elderly people. Int J Dermatol; 2010 Aug;49(8):907-13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We analyzed data from 849 consecutive patients with stage III cutaneous melanoma who were treated between 1994 and 2007 at one institution.
  • Independent negative prognostic factors of DSS in the group of older stage III patients were identified as features of nodal metastases (extracapsular invasion, HR = 1.74, P = 0.009; and ≥ 4 involved lymph nodes, HR = 1.5; P = 0.008) and male sex (HR = 1.5; P = 0.039).
  • CONCLUSIONS: This analysis showed that melanoma patients ≥ 65 years of age are characterized by a higher primary tumor stage and worse prognosis in the presence of regional node metastases than younger patients.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Incidence. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Prognosis. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The International Society of Dermatology.
  • (PMID = 21174374.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W: Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. Ann Surg Oncol; 2006 Dec;13(12):1655-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The FN SLN biopsy results correlated with primary tumor thickness >4 mm (P = .0012), primary tumor ulceration (P = .0002), primary tumor level of invasion Clark stage IV/V (P = .0005), and nodular melanoma histological type (P = .0375).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. False Negative Reactions. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Predictive Value of Tests. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17016755.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Nowecki ZI, Rutkowski P, Michej W: The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3). Ann Surg Oncol; 2008 Aug;15(8):2223-34
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of our study was to assess the overall survival (OS; calculated both from the date of primary tumor excision and lymph node dissection) data from two large groups of AJCC 2002 stage-III cutaneous melanoma patients-after completion lymph node dissection (CLND after positive sentinel node biopsy) and after therapeutic LND (TLND for clinically/cytologically detected regional lymph node metastases).
  • [MeSH-minor] Adult. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18506535.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Rutkowski P, Nowecki ZI, Dziewirski W, Zdzienicki M, Pieñkowski A, Salamacha M, Michej W, Trepka S, Bylina E, Ruka W: Melanoma without a detectable primary site with metastases to lymph nodes. Dermatol Surg; 2010 Jun;36(6):868-76
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We included data from 459 consecutive patients treated from 1994 to 2007 with radical therapeutic lymph node dissection (LND; stage IIIB, C) due to clinically palpable and pathologically confirmed lymph node metastases (229 axillary; 230 ilioinguinal).
  • Thus, all MUP cases should be treated as standard stage III melanomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Cohort Studies. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20482725.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Rutkowski P, Nowecki ZI, Kulik J, Ruka W, Siedlecki JA: Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection. Melanoma Res; 2008 Aug;18(4):246-52
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We collected 24-h lymph fluid (LY) and peripheral blood (BL) from 107 stage III melanoma patients after radical LND (59 axillary and 48 ilioinguinal LND).
  • The LY MM RT-PCR seems to be an effective prognostic tool for stage III melanoma patients.
  • [MeSH-minor] Adult. Aged. Disease Progression. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplastic Cells, Circulating. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Skin Neoplasms / blood. Skin Neoplasms / mortality. Skin Neoplasms / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18626308.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


95. Doglietto GB, Tortorelli AP, Papa V, Rosa F, Bossola M, Prete FP, Covino M, Pacelli F: Giant retroperitoneal sarcomas: a single institution experience. World J Surg; 2007 May;31(5):1047-54
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Retroperitoneal sarcomas (RS) are a rare group of malignant soft-tissue tumors; due to the flexibility of the retroperitoneum, they generally grow to a large size before becoming symptomatic, often involving surrounding structures.
  • Advanced stage, incomplete gross surgical resection, higher tumor grade, non-liposarcoma histology and microscopic infiltration of margins were found to be significantly negative prognostic factors.
  • [MeSH-major] Retroperitoneal Neoplasms / surgery. Sarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Prognosis. Proportional Hazards Models. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Jun 1;100(11):2448-55 [15160351.001]
  • [Cites] Eur J Surg Oncol. 1993 Aug;19(4):355-60 [8395410.001]
  • [Cites] World J Surg. 1999 Jul;23(7):670-5 [10390584.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):244-50 [14745333.001]
  • [Cites] Surgery. 1989 Oct;106(4):725-32; discussion 732-3 [2799648.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] Br J Surg. 2005 Feb;92(2):246-52 [15505870.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):669-75 [16003776.001]
  • [Cites] Ann Surg Oncol. 1997 Jul-Aug;4(5):421-4 [9259970.001]
  • [Cites] Am Surg. 2002 Jan;68(1):52-6 [12467318.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):483-90 [15078637.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • (PMID = 17345124.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Keizman D, Issakov J, Meller I, Maimon N, Ish-Shalom M, Sher O, Merimsky O: Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J Neurooncol; 2009 Sep;94(3):383-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma.
  • Forty-three percentage of 46 patients with MPNST overexpressed EGFR in the primary tumor, and had a higher prevalence of advanced-stage tumors (>or=IIc, 46% vs. 80%, P = 0.011).
  • [MeSH-minor] Adult. Cohort Studies. Female. Humans. Logistic Models. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurooncol. 2009 Sep;94(3):389. Meimon, Natalie [corrected to Maimon, Natalie]
  • [Cites] Oncologist. 2008 Apr;13(4):459-66 [18448562.001]
  • [Cites] Semin Oncol. 2003 Feb;30(1 Suppl 1):3-11 [12644979.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4507-13 [12154062.001]
  • [Cites] Cancer. 2005 May 1;103(9):1881-90 [15772959.001]
  • [Cites] Cell Signal. 2007 Oct;19(10):2013-23 [17681753.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Aug;61(8):702-9 [12152785.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):102-8 [15598946.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2445-59 [15753456.001]
  • [Cites] Brain Pathol. 2004 Jul;14(3):297-303 [15446585.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2787-99 [12860957.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):585-90 [16461571.001]
  • [Cites] Sarcoma. 2008;2008:849156 [18769552.001]
  • [Cites] Am J Clin Pathol. 2006 Feb;125(2):229-33 [16393679.001]
  • [Cites] Cancer. 2006 Sep 1;107(5):1065-74 [16881077.001]
  • [Cites] Neurosurg Focus. 2007 Jun 15;22(6):E12 [17613203.001]
  • [Cites] J Surg Oncol. 2007 Mar 1;95(3):183-4 [17323329.001]
  • [Cites] Eur J Surg Oncol. 2006 May;32(4):466-8 [16524687.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] Neuro Oncol. 2008 Dec;10 (6):946-57 [18650488.001]
  • [Cites] Br J Cancer. 1998 Jun;77(11):1792-8 [9667648.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] J Surg Orthop Adv. 2005 Winter;14(4):168-74 [16442014.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] World J Surg Oncol. 2006 Aug 22;4:55 [16923196.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4057-65 [17827454.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1331-46 [11571750.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Breast Cancer. 2002;9(2):111-7 [12016390.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1201-8 [14993230.001]
  • [Cites] Cancer Cell. 2005 Jan;7(1):65-75 [15652750.001]
  • (PMID = 19330289.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


97. Torroni A, Gennaro P, Aboh IV, Longo G, Valentini V, Iannetti G: Microvascular reconstruction of the mandible in irradiated patients. J Craniofac Surg; 2007 Nov;18(6):1359-69
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This work focuses on the use of revascularized free flaps for the reconstruction of the major defects of the mandible after the removal of advanced-stage tumors in irradiated patients.
  • In each case, secondary reconstruction of the mandible and soft tissue was necessary and was performed using microvascular free flaps.
  • [MeSH-minor] Adenocarcinoma / radiotherapy. Adenocarcinoma / rehabilitation. Adenocarcinoma / surgery. Adult. Anastomosis, Surgical. Bone Plates. Bone Transplantation. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / rehabilitation. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Malocclusion / etiology. Malocclusion / surgery. Microsurgery. Middle Aged. Parotid Neoplasms / radiotherapy. Parotid Neoplasms / rehabilitation. Parotid Neoplasms / surgery. Reoperation. Sarcoma, Synovial / radiotherapy. Sarcoma, Synovial / rehabilitation. Sarcoma, Synovial / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17993882.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Akiode O, Shonubi AM, Musa A, Sule G: Major limb amputations: an audit of indications in a suburban surgical practice. J Natl Med Assoc; 2005 Jan;97(1):74-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case notes of all patients who had major limb amputations were examined for patients' age, sex, time of presentation, limb affected, indications for amputation, the severity of crush injury to limb, stage of musculoskeletal tumors and Wagner's grade of diabetic foot.
  • Out of the 15 salvageable limbs, there were 11 cases of clean-cut traumatic amputations, two of soft-tissue sarcoma and one each of ruptured popliteal aneurysm and stenosed popliteal artery.
  • [MeSH-minor] Adult. Amputation, Traumatic / epidemiology. Bone Neoplasms / epidemiology. Bone Neoplasms / surgery. Diabetic Foot / epidemiology. Diabetic Foot / surgery. Female. Humans. Male. Medical Audit. Nigeria. Peripheral Vascular Diseases / epidemiology. Peripheral Vascular Diseases / surgery. Retrospective Studies. Salvage Therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trop Doct. 2000 Jul;30(3):133-5 [10902466.001]
  • [Cites] East Afr Med J. 1999 Mar;76(3):163-6 [10442118.001]
  • [Cites] Ann Surg Oncol. 2001 Jul;8(6):509-18 [11456050.001]
  • [Cites] Ann Vasc Surg. 2003 Jan;17(1):86-90 [12522704.001]
  • [Cites] Vasc Endovascular Surg. 2003 Mar-Apr;37(2):99-104 [12669140.001]
  • [Cites] Afr J Med Med Sci. 2002 Dec;31(4):333-6 [15027774.001]
  • [Cites] Foot Ankle. 1983 Jan-Feb;3(4):197-202 [6131856.001]
  • [Cites] Tohoku J Exp Med. 1983 Dec;141 Suppl:575-82 [6680534.001]
  • [Cites] J Trauma. 1985 Dec;25(12):1147-50 [3934398.001]
  • [Cites] Clin Orthop Relat Res. 1990 Jul;(256):80-6 [2194732.001]
  • [Cites] J Hand Surg Am. 1991 Jan;16(1):117-21 [1995666.001]
  • [Cites] Ann R Coll Surg Engl. 1991 May;73(3):137-42 [2042888.001]
  • [Cites] J Hand Surg Am. 1991 Jul;16(4):574-84 [1880353.001]
  • [Cites] Surg Gynecol Obstet. 1992 Nov;175(5):389-96 [1440165.001]
  • [Cites] Can J Surg. 1995 Jun;38(3):221-8 [7788601.001]
  • [Cites] Orthopedics. 1995 Jul;18(7):665-72 [7479406.001]
  • [Cites] Bull Hosp Jt Dis. 1996;55(1):46-52 [8771355.001]
  • [Cites] Surg Today. 1997;27(2):130-4 [9017989.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(2):159-61 [9676328.001]
  • [Cites] Surgery. 2000 Sep;128(3):472-9 [10965320.001]
  • (PMID = 15719875.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2568563
  •  go-up   go-down


99. Sakamoto M, Murakawa T, Kitano K, Murayama T, Tsuchiya T, Nakajima J: Resection of solitary pulmonary lesion is beneficial to patients with a history of malignancy. Ann Thorac Surg; 2010 Dec;90(6):1766-71
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • History of cancers other than colorectal and bone and soft tissue sarcoma and shorter disease-free interval were indicators of poor prognosis.
  • Pathologic stage was the only indicator of prognosis for primary lung cancer, and none of the factors concerning antecedent cancer influenced prognosis.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bronchoscopy. Child. Diagnosis, Differential. Disease-Free Survival. Female. Follow-Up Studies. Humans. Japan / epidemiology. Male. Middle Aged. Positron-Emission Tomography. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] Ann Thorac Surg. 2010 Dec;90(6):1771-2 [21095306.001]
  • (PMID = 21095305.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


100. Ramamurthy R, Bose JC, Muthusamy V, Natarajan M, Kunjithapatham D: Staged sacrectomy--an adaptive approach. J Neurosurg Spine; 2009 Sep;11(3):285-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Object Sacral tumors are commonly diagnosed late and therefore present at an advanced stage.
  • Sacrectomy is fraught with a high local recurrence rate and potential complications: deep infection; substantial blood loss; large-bone and soft-tissue defects; bladder, bowel, and sexual dysfunction; spinopelvic nonunion; and gait disturbance.
  • Histological diagnosis included giant cell tumor, chordoma, chondroblastoma, adenocarcinoma of rectum, and retroperitoneal sarcoma.
  • [MeSH-minor] Adolescent. Adult. Cohort Studies. Female. Humans. India. Male. Middle Aged. Retrospective Studies. Surgical Wound Dehiscence / etiology. Surgical Wound Dehiscence / therapy. Survival Rate. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19769509.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement